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ABSTRACT OF THE DISSERTATION
RhoA Mediated Juxtacrine Regulation of Glucagon Secretion
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Professor David W. Piston

Glucagon is secreted from pancreatic islet alpha-cells in response to hypoglycemia. The
regulation of this secretion likely involves multiple interacting molecular pathways. There are
three general types of proposed models for glucose-dependent regulation of glucagon secretion:
direct regulation by glucose mediated modulation of cell electrophysiology, paracrine regulation
by other endocrine cell types within the islets of Langerhans, and juxtacrine regulation by
surface protein interactions from neighboring beta-cells. This work is focused on one pathway of
juxtacrine regulation that occurs through signaling from EphA4 receptors on the surface of αcells upon interaction with ephrin-A5 ligands on the surface of beta-cells. In this pathway,
stimulation of EphA4 leads to a dense F-actin network that inhibits the secretion of glucagon
vesicles. In this work, we present evidence that RhoA, a Rho family GTPase, links EphA4
stimulation to F-actin polymerization and is required for the formation of cortical actin networks.
Pharmacological inhibition of RhoA, but not Cdc42 or Rac1, resulted in the disruption of proper
glucose-inhibition of glucagon secretion. We showed that EphA4 stimulation increase RhoA
activity through direct visualization and quantification using a FRET biosensor reporting on

xii

RhoA activity. Using a fluorescent nanobody for F-actin, we also showed that RhoA activity and
F-actin formation are correlated. Further, quantitative imaging of intracellular Ca2+ using Ca2+
biosensors showed that RhoA activity modulates intracellular Ca2+ activity. These results
implicate RhoA as the key regulator of F-actin in the EphA/Ephrin-A juxtacrine regulation
pathway and suggest a larger role of RhoA as a signaling hub facilitating crosstalk between the
different regulatory pathways.
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Chapter 1
Introduction

1.1

Introductory Comments
The goal of the work presented here is focused on the regulation of glucagon secretion in

the pancreatic islets of Langerhans. Previous work in our lab identified the EphA/Ephrin-A
signaling pathway to be a critical juxtacrine regulatory mechanism of glucagon secretion,
demonstrating the importance of the physical architecture of the islet. The work presented here
provides evidence for RhoA as a key intermediary in this pathway. Chapter 1 provides
background information about the significance of glucose homeostasis, the function of pancreatic
islets in maintaining glucose homeostasis, the roles of glucose regulating hormones insulin and
glucagon secreted in the islets, the mechanisms of regulation of these hormones in the islets, and
the dysregulation of these hormones in diabetes. Chapter 2 describes the characterization of the
effects of RhoA in glucagon secretion. Chapter 3 presents the evidence RhoA acts downstream
of EphA signaling in this regulatory pathway. Chapter 4 explores the role of RhoA in glucagon
secretion outside the context of the EphA/Ephrin-A juxtacrine regulatory pathway. Chapter 5
discusses the significance and the future direction of the research presented in the previous
chapters.

1.2

Glucose Homeostasis
As one of the primary sources of energy sustaining mammalian life, glucose is tightly

regulated. In humans, circulating blood glucose levels are maintained in a small range (~4.0-9.0
1

mM / ~70-160 mg/dl) (1) despite large fluctuations in glucose supply and demand, such as
fasting, exercise, and heavy carbohydrate ingestion. Deviation from this range can have
deleterious health effects. Hypoglycemia, or low blood glucose levels, can lead to cellular
starvation and death, especially in the brain (2), which, in normal physiological conditions, relies
almost exclusively on circulating glucose for energy due to the blood-brain barrier (3).
Hyperglycemia, or high blood glucose levels, can result in tissue damage through osmotic and
oxidative stresses, as well as dysfunction of metabolic pathways and generation of glucotoxins
(4). Chronic elevation of glucose can lead to numerous complications, such as retinopathy,
neuropathy, and nephropathy. Thus, proper glucose homeostasis is highly important.
The liver and pancreas are the primary organs involved in the regulation of glucose
homeostasis (Figure 1) (1, 5). The liver functions as the primary storage organ for glucose as
glycogen. In the pancreas, the islets of Langerhans are responsible for the endocrine function of
the organ. Among the many endocrine factors secreted by the pancreatic islets, the hormones
insulin and glucagon are the primary regulators of glucose storage and release in the liver in
response to circulating blood glucose levels (5, 6). In addition to the liver and pancreas, skeletal
muscle and adipose tissue also play a major part in glucose clearance (7). Skeletal muscle acts as
a glucose reservoir and is responsible for storage of most of the glucose ingested. Adipose tissue
is important not only for their role in glucose storage but is responsible for endocrine signaling
through secretion of factors such as leptin and adiponectin.
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Figure 1. Simplified schematic of glucose homeostasis. Black arrows represent causal or
stimulatory processes. Red flathead arrows represent inhibition of the processes involved.

1.3

The Pancreatic Islets of Langerhans

1.3.1 Overview
The pancreatic islets of Langerhans are micro-organs within the pancreas responsible for
its endocrine function first described in 1869 (8). They are roughly spherical, collagenencapsulated clusters having an average size of ~100 µm containing ~1,000 to 10,000 cells (912). The islets are highly vascularized, receiving 10-15% of the total pancreatic blood supply
despite accounting for only 1-2% of the pancreatic mass (13, 14). This vasculature allows for
rapid sensing of changes to blood glucose levels and subsequent response by secreting the
appropriate hormones to restore euglycemia. One interesting aspect of pancreatic islets is that the
size of pancreatic islets is relatively conserved across organisms of all sizes, and it is the number
of islets instead that is correlated (10, 15, 16). This provides first indication of the importance of
the islet architecture in its function.
3

1.3.2 The Pancreatic Islet Architecture
The islet consists of several different cell types. Insulin secreting β-cells, glucagon
secreting α-cells, and somatostatin secreting δ-cells are the primary cell types present (12, 1720). Other cell types that make up <5% of the islet include pancreatic polypeptide secreting PPcells and ghrelin secreting ε-cells. β-cells are the most abundant in islets, followed by α-cells and
then to a lesser extent δ-cells. The composition and cytoarchitecture of the pancreatic islets differ
between species (Figure 2). Murine islets consist of ~75% β-cells, ~20% α-cells, and ~5% δ-cells
arranged as a mantle of α- and δ-cells surrounding a core of β-cells. Human islets consist of

Figure 2. Comparison between mouse and human pancreatic islets. Pancreatic islets are
made up of primarily insulin secreting β-cells (green), glucagon secreting α-cells (red), and
somatostatin secreting δ-cells (blue). Several key differences exit between murine and human
islets. In mice, the islets form a structured cytoarchitecture with α- and δ- cells surround a βcell core. Human islets show a more randomly distributed cytoarchitecture as well as a higher
relative amount of α- and δ- cells compared to mouse islets.
4

~50% β-cells, ~40% α-cells, and ~10% δ-cells arranged as a random distribution throughout the
islet (21-23). Although it is unclear why these differences exist, they suggest a possible link
between islet architecture plasticity and the different metabolic demands among different
species.
The islet is far from being just a simple cluster of cells. The α-, β-, and δ-cells all lose
normal function and impaired glucose response upon dispersion of the islet (24-29),
demonstrating the necessity of the islet environment proper function of the different cell types. A
closer inspection of the islet reveals the high degree of intercellular connectivity and
communication between the endocrine cells (Figure 3). These interactions include direct contact
interactions such as gap junctions (30, 31), tight junctions (32), and surface protein interactions
(33, 34), but also paracrine interactions via hormone receptors (20, 35-37) utilizing the interstitial
space within the islet as well as the bloodstream through the extensive vasculature throughout the
islet (38-41). More recent studies showed that the primary cilia in the interstitial space (42) play
an important role in signaling between the endocrine cells and in maintenance of their proper
physiological functions (43-47). In addition, islets are highly innervated (48), providing an
additional level of intraislet and interislet coordination. These interactions demonstrate the
complexity of the islet which is most likely necessary to provide a robust control of hormone
secretion in response to physiological changes in circulating glucose. However, much of the
details surrounding the communication pathways and the interconnection between them is
relatively unknown.
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Figure 3. Intercellular communication between endocrine cells in the pancreatic islet.
The hormone secreting cells in the pancreatic islets show a high degree of connectivity and
communication through a number of signaling pathways. Some pathways involve direct
contact, such as through various types of junctions and membrane protein interactions, but
can also signal remotely through secreted hormones and their respective receptors in
neighboring cells in a type of signaling called paracrine signaling.

6

1.4

Insulin and the β-Cell

1.4.1 Insulin Function
First discovered in 1922 by Sir Frederick Banting and Charles Best, a discovery which
saw the former share the Nobel Prize a year later, insulin is the hormone primarily responsible
for lowering blood glucose. Insulin is a highly conserved 51-amino acid peptide dimer linked by
two disulfide bonds (49). It is secreted exclusively in β-cells through exocytosis as zinccoordinated hexamers (50). Secretion is maximal at high blood glucose and minimal at low
blood glucose. Secreted insulin binds to the insulin receptor (IR), which is a receptor tyrosine
kinase (RTK) expressed in a wide range of tissue types including liver, muscle, and adipose
tissues. Insulin binding leads to autophosphorylation of the IR and subsequent conformational
change that promotes kinase activity (51). The downstream effects of IR signaling results in
multiple changes in metabolic processes in the cell. Glucose uptake into the cell is promoted
through the translocation of the glucose transporter GLUT4 to the plasma membrane through the
phosphatidylinositol 3-kinase (PI3K) (52, 53), and glycogenesis is promoted to convert glucose
to glycogen for storage by activation of glycogen synthase (54). In addition, gluconeogenesis and
glycogenolysis is inhibited by phosphoprotein phosphatase-1 (PP1) mediated inhibition of key
enzymes in these metabolic processes (55, 56). In addition, insulin signaling in the hypothalamus
suppresses food intake (57, 58), demonstrating the coordinated signaling of insulin at both the
cellular and behavioral levels to decrease circulating blood glucose levels upon hyperglycemia to
maintain glucose homeostasis.
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1.4.2 Glucose-Stimulated Insulin Secretion
Due to the therapeutic success of insulin in treating diabetes, the concentrated scientific
efforts in β-cell research in the past century resulted in a well-understood consensus model of the
regulatory pathway of insulin secretion β-cells (Figure 4) (59, 60). In this multi-step pathway,
referred to as glucose-stimulated insulin secretion (GSIS), circulating blood glucose is taken up
by the glucose transporter GLUT2. The internalized glucose is then processed by the
mitochondria through glycolysis and the TCA cycle, resulting in an elevation of ATP/ADP ratio
(61-63). This shift in the ATP/ADP ratio leads to the closure of ATP-dependent potassium
(KATP) channels by direct inhibition, leading to membrane depolarization (64, 65).
Depolarization of the membrane causes the opening of voltage dependent L-type Ca2+ channels
and subsequent influx of extracellular calcium (66-67). This increase in intracellular calcium
([Ca2+]i)triggers the calcium-dependent exocytosis of insulin vesicles. (68, 69), which lasts until
the membrane repolarizes. Excess Ca2+ is transported to the endoplasmic reticulum by Ca2+
ATPases, lowering both [Ca2+]i and the ATP/ADP ratio (69). Elevated [Ca2+]i also causes the
opening of calcium- and voltage-dependent rectifying K+ channels (69-71) that repolarizes the
membrane through K+ efflux. Once repolarized, the cycle of depolarization and repolarization
can start again upon metabolization of more glucose, leading to pulsatile insulin secretion
coupled to intracellular Ca2+ oscillations. Interestingly, this oscillatory behavior is synchronized
between all β-cells within an islet despite what is a stochastic molecular process. This is made
possible due to the cells being electrically coupled through gap junctions (72). The
synchronization functions to enhance sensitivity to glucose by ensuring all β-cells are inactive or
fully active at low and high glucose conditions, respectively (73-75).
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Figure 4. Consensus model of glucose-stimulated insulin secretion (GSIS) in β-cells. In
this model, circulating blood glucose is take into the cell by glucose transporters, which is
then metabolized by the mitochondria to generate ATP. The increase in [ATP] causes the
inhibition of KATP channels, leading to membrane depolarization and subsequent activation of
voltage gated Ca2+ channels. The opening of these channels leads to an influx of extracellular
Ca2+, driving Ca2+ dependent vesicle exocytosis.

1.4.3 Intraislet Regulatory Mechanisms of Insulin Secretion
Although the GSIS pathway is the primary mechanism in which β-cells regulate insulin
secretion, the islet environment gives rise to many additional intraislet mechanisms of β-cell
regulation. The islet-mediated forms of regulation fall into two types: paracrine and juxtacrine.
Paracrine signaling occurs when a hormone secreted from one cell acts on a remote cell.
Juxtacrine signaling occurs between cells in direct physical contact and between surface
membrane proteins.

9

Paracrine signaling in the islet occurs primarily though glucagon from α-cells and
somatostatin from δ-cells. Glucagon has been shown to bind to glucagon receptors on β-cells and
has a stimulatory effect on insulin secretion by raising intracellular cAMP levels (76, 77).
Somatostatin has been shown to have the opposite effect on insulin secretion by binding to
somatostatin receptors to decrease intracellular cAMP levels (78). A special subset of paracrine
signaling, autocrine signaling can occur in β-cells as the secreted molecules can regulate its own
secretory behavior. Insulin, as well as serotonin and dopamine that are co-secreted with insulin,
have all been reported to affect insulin secretion. Studies have shown serotonin and dopamine
have a negative feedback role in insulin secretion. Serotonin binds to serotonin 1A receptor
(5HT1A) to decrease intracellular cAMP (79), and dopamine binds to dopamine receptor D3
(DRD3) to disrupt proper [Ca2+]i activity (80). The autocrine effect of insulin, however, is less
clear, as different groups have provided evidence for an inhibitory role of insulin (81, 82) as well
as a stimulatory role (83, 84).
Juxtacrine signaling takes place through direct physical contact between two cells. Cell
adhesion molecules (CAMs) and the EphA/ephrin-A proteins have been shown to play a role in
the proper regulation of insulin secretion in β-cells. Various CAMs are expressed in islets,
including E-, N-, T-cadherins and neural cell adhesion molecules (NCAMs), with NCAMs
preferentially expressed in non β-cells (85). In addition to their role in islet development and
preserving islet architecture (85, 86), CAMs are involved in regulating insulin secretion. Loss of
E-cadherin (87-89) and NCAM function attenuated GSIS (90), possibly though interaction with
β-catenin (91, 92). Loss of N- and T-cadherin function also resulted in impairment of proper
insulin secretion by disrupting vesicle dynamics (93, 94). Cadherins also have a role in
regulating β-cell proliferation and apoptosis (88, 95, 96), demonstrating their multifaceted
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importance in the context of the pancreatic islet and β-cells. Another form of juxtacrine
regulation occurs through EphA/Ephrin-A signaling. In β-cells, EphA5 and ephrin-A5 are highly
expressed (97-99). The bidirectional signaling of EphA5/ephrin-A5 was shown to be
antagonistic, with EphA5 forward signaling suppressing insulin secretion and ephrin-A5 reverse
signaling stimulating insulin secretion (99). This regulatory mechanism was proposed to function
through protein tyrosine phosphatases (PTPs) where PTP-mediated dephosphorylation of EphA5
at high intracellular glucose concentrations inhibits downstream signaling, allowing the ephrinA5 reverse signaling to dominate. Disruption of the forward signaling through pharmacological
inhibition of Eph receptors resulted in increased insulin secretion and increased glucose tolerance
in mice (100, 101). The EphA/ephrin-A signaling system will be discussed in more detail in
Chapter 2.
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1.5

Glucagon and the α-Cell

1.5.1 Glucagon Function
Glucagon was first described by Charles Kimball and John Murlin in 1923 as a glucose
agonist (102), although its importance in physiology and glucose homeostasis was not
established until the 1970s (103). Glucagon is synthesized in α-cells initially as part of the larger
preproglucagon that is doubly and cell-specifically cleaved to generate the 29-amino acid peptide
(104, 105). Glucagon is counterregulatory to insulin and functions to increase circulating blood
glucose, with maximal production in low blood glucose conditions and minimal production in
high blood glucose conditions. Glucagon binds to and signals through the glucagon receptor, a
G-protein coupled receptor, primarily in the liver but also in other tissue types such as kidney,
adipose, and intestinal smooth muscle tissues (103, 106). Upon binding of glucagon, the receptor
activates adenylyl cyclase (AC). Activation of AC stimulates the generation of cAMP, which
then activates protein kinase A (PKA). Increased PKA activity promotes glycogenolysis and
gluconeogenesis (55, 107).

1.5.2 Glucose Inhibition of Glucagon Secretion
In contrast to the well characterized regulatory mechanisms of insulin secretion in β-cells,
regulation of glucagon secretion is still shrouded in mystery, although interest in the field is
growing in conjunction with growing recognition of the importance of glucagon in the
pathophysiology of diabetes. Unlike in the case of insulin and β-cells, no consensus model exists
for the glucose inhibition of glucagon secretion (GIGS). Initial hypotheses attempted to utilize
known mechanisms in GSIS to explain glucagon secretion but were quickly proven to be
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Figure 5. Secretion profiles of insulin and glucagon. (A) Secretion of insulin and glucagon
in intact islets shows their opposing secretory behavior. In response to increasing glucose
concentrations, insulin secretion increases (black circles) while glucagon secretion decreases
(gray squares), with maximal changes occurring between 1 and 10 mM glucose. (B) The
secretion profiles of glucagon are markedly different in intact islets (solid squares) and
dispersed α-cells (open squares). In contrast to the physiological secretory response to
glucose, glucagon secretion increases with increasing glucagon concentration. In addition,
secretion of glucagon from dispersed α-cells are elevated at all concentrations of glucose.
Reproduced with permission from (28).

inconsistent due to two key observations (Figure 5): first, glucagon secretion tracks inversely
with insulin, and secondly, the suppression of glucagon secretion at high glucose is abolished
and instead increased when α-cells are dispersed and removed from the islet environment (28),
suggesting that the intrinsic glucose-sensing regulatory pathway is not the primary pathway.
These two observations provide first indication of the inadequacy of a simple GSIS-like model
for α-cells. Recent efforts in glucagon research have put forth many hypotheses to explain GIGS
that can be classified into three classes: intrinsic/electrophysiological regulation, juxtacrine
regulation, and paracrine regulation (Figure 6).
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Figure 6. Regulatory mechanisms of glucagon secretion in α-cells. Current models of
glucagon secretion in α-cells fall into three categories that work in concert to maintain GIGS:
intrinsic (electrophysiological), paracrine, and juxtacrine. The intrinsic model functions
similarly to the consensus model in GSIS as glucose uptake and calcium influx is required for
glucagon secretion. However, differential expression and function of the different ion
channels result in the inverted response to glucose. Paracrine models consist of the signaling
pathways triggered by secretory products from neighboring cells, primarily insulin and
somatostatin, that modulate ion channel activity and intracellular cAMP levels. Juxtacrine
models involve the tonic signaling arising requiring direct contact between cells, such as
EphA4/7 signaling through contact with ephrin-A5 from adjacent β-cells.
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1.5.3 Intrinsic/Electrophysiological Regulation of Glucagon Secretion
Like in insulin secretion in β-cells, α-cells require Ca2+ influx events for secretion (108110). Furthermore, α-cells also have glucose transporters, KATP channels, and voltage-dependent
Ca2+ channels like in β-cells (111-113). The similarities between the two cell types serves to add
to the mystery of the paradoxical secretory response to glucose in α-cells. In fact, Ca2+ activity in
α-cells, which in β-cells serves as a reliable proxy for secretion, has been shown to decouple
from glucagon secretion at high glucose concentrations (28, 110, 114), signifying the presence of
regulatory pathways independent of Ca2+. Investigative efforts have provided insight into the
electrophysiological behavior of α-cells and have observed several key differences between the
two cell types.
KATP channels are also critical to α-cell function, as loss of KATP channel function by
genetic knockout or pharmacological inhibition resulted in defects of glucagon secretion (108,
115). However, they have also been found to be largely inactivated in α-cells even in low
glucose conditions, tuning the sensitivity window of glucose and ATP/ADP ratio to a lower
glucose concentration (109, 116, 117). This allows for α-cells to be able to fire spontaneous
action potentials in low glucose conditions and secrete glucagon. The difference in KATP channel
activity provides a mechanism of glucagon secretion at low glucose conditions but fails to
address the inhibition of glucagon secretion at high glucose concentrations.
Differences in voltage-dependent Ca2+ channel activity and expression have been
reported to be involved in GIGS. It is hypothesized that the differential expression of various ion
channels in α-cells creates a narrow window of membrane potential that can sufficiently trigger
secretion (118, 119). L-type Ca2+ channels, while most abundant in α-cells, were shown to play a
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minimal role in secretion in low glucose conditions (120, 121). Instead, P/Q-type Ca2+ channels
seem to play a leading role (109). Upon increase in glucose uptake and metabolization, KATP
channels are further inactivated, depolarizing the membrane enough to inactivate voltagedependent T-type Ca2+ and Na+ channels, which then decreases the generated action potential
amplitude enough to become unable to trigger P/Q-type Ca2+ activity and subsequent Ca2+ influx
required for vesicle secretion.
The intrinsic/electrophysiological regulatory pathway alone is insufficient in explaining
the secretory behavior of α-cells, as the models described above fail to explain the reversed
behavior of α-cells upon dispersion. In addition, further investigation into the electrophysiology
of α-cells is made significantly more challenging due to heterogeneity in the cell population.
Although heterogeneity also exists in β-cells in terms of their development, morphology, and
function (122), they display remarkable synchronization in their Ca2+ response to a glucose
stimulus (Figure 7) due to their electrical connectivity through gap junctions. Conversely, α-cells
exhibit no such synchronous behavior as no evidence of electrical connectivity among α-cells has
been reported. Studies have observed that even within the same islet, α-cells display a range of
behaviors in response to glucose (28, 110, 123). While synchronous Ca2+ oscillations were
observed in some cells, it was not observed in others. While Ca2+ activity was lost upon exposure
to elevated glucose concentrations in some cells, activity was preserved in others. While increase
in [Ca2+]i was measured in some cells, a decrease was measured in others. This heterogeneity is
likely to have functional importance that is yet unknown. However, improving our understanding
of this heterogeneity is likely necessary to be able to generate a more accurate model of α-cell
electrophysiology.

16

Figure 7. Electrophysiological heterogeneity in α-cells. Kymographs from confocal
imaging of Ca2+ activity from β-cells in intact islets (A) reveals the occurrence of highly
synchronous Ca2+ influx events, while no such synchronization is observed from α-cells in
intact islets (B).

1.5.4 Paracrine Regulation of Glucagon Secretion
Paracrine regulation in α-cells occurs primarily through insulin and somatostatin, both
which have an inhibitory effect on glucagon secretion. In addition, Zn2+ and γ-aminobutyric acid
(GABA), both factors co-secreted with insulin from β-cells, also have proposed inhibitory
effects. Each factor has evidence supporting a role in inhibiting vesicle exocytosis by inhibiting
depolarization events: Insulin through modulating KATP channel activity (124, 125), somatostatin
through activation of GIRK channels (126), Zn2+ through opening of KATP channels (125, 127),
and GABA through activation of GABAA-receptor Cl- channels (128).
More recently, a Ca2+ independent mode of paracrine regulation has been postulated.
Insulin and somatostatin bind to their respective receptors, IR and somatostatin receptor 2
(SSTR2), on the surface of α-cells and has been shown to cooperatively suppress glucagon
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secretion by reducing intracellular cAMP (129). Insulin promotes cAMP degradation by
activating phosphodiesterase 3B and somatostatin inhibits production of cAMP by inhibition of
AC. This observation has been supported in vivo as genetic knockout of α-cell-specific IR and
SSTR2 both resulted in defective GIGS in mice (35, 130).
The paracrine regulatory mechanisms described above help explain the inhibition of
glucagon secretion in high glucose conditions. However, this model alone fails to explain why
secretion occurs in low glucose conditions when β- and δ-cells are inactive. Furthermore, at
intermediate glucose conditions, glucagon secretion decreases before any changes to insulin and
somatostatin secretion (19, 119, 131). In addition, treatment with individual paracrine factors
does not suppress glucagon secretion in dispersed α-cells (28). Interestingly, insulin and
somatostatin were able to suppress glucagon secretion when applied together (129), suggesting
the importance of the cooperative effect of the two paracrine hormones. Although paracrine
regulation is an important component of proper glucagon secretion, these results indicate that
there are many aspects of the islet that our current state of understanding and proposed models
are still inadequate to explain these phenomena.

1.5.5 Juxtacrine Regulation of Glucagon Secretion
Similar to what was described previously in β-cells, juxtacrine regulation occurs in αcells primarily through contact with β-cells. EphA/Ephrin-A and NCAMs have been reported to
be important juxtacrine factors in maintaining proper GIGS. EphA4 in the α-cells has been
shown to suppress glucagon secretion by modulating F-actin density (34) through interactions
with ephrin-A5 expressed on the surface of β-cells. Loss of NCAM function by genetic knockout
resulted in impaired GIGS, likely through loss of F-actin modulating function (90). In addition,
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tight junctions have been observed specifically between β- and α-cells (132), but their role in the
regulation of glucagon secretion remains unknown. EphA/Ephrin-A signaling will be discussed
in greater detail in Chapter 2.

1.6

Diabetes Mellitus

1.6.1 Overview of Diabetes
Diabetes describes a family of metabolic disorders characterized by the loss of ability to
maintain glucose homeostasis, resulting in chronic hyperglycemia. If left untreated, chronic
hyperglycemia can lead to damage and dysfunction in organs including kidneys and heart.
Diabetes affects over 460 million people globally with prevalence expected to continue to rise to
over 700 million by 2045 (133). The scale of impact of diabetes is reflected in its societal and
economic costs, with 4.2 million attributable deaths and health care costs of $760 million in 2019
alone (134, 135). Type 2 diabetes (T2D) is the most prominent form of diabetes, accounting for
>90% of cases (136), followed by Type 1 (T1D) making up >5% (137). Other rarer forms of
diabetes, such as gestational (138) and monogenic diabetes (139), also occur.

1.6.2 Type 2 Diabetes
T2D manifests in patients in a variety of physiological disorders such as insulin
resistance, insulin deficiency, and β-cell failure and death (140). Β-cell dysfunction lies at the
core of T2D, with disruption in all stages of insulin physiology from expression (141) and
secretion (142, 143) to signaling (144). Inhibited glucose tolerance and hyperglycemia are
characteristic of T2D patients, as well as elevated plasma insulin levels to compensate for
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peripheral insulin resistance. Increase in β-cell mass due to proliferation can be observed in T2D
patients as an initial response to insulin resistance (145). The progression of the disease
ultimately leads to β-cell failure and death as a result of the stress induced by the persistent
increase in compensatory insulin demand.
Development and progression of T2D is heavily dependent on a multitude of factors, both
genetic and environmental. Genes involved in β-cell development and function have been
identified to be linked to increased T2D risk (146). The existence of a genetic risk in T2D can be
seen in the increased prevalence of T2D in first-degree relatives of patients (147, 148) and in
certain ethnic groups (149, 150). Among the environmental factors, obesity and physical
inactivity are the two most prominent (151). Although the exact mechanisms of these two
environmental risk factors are still unknown, they are hypothesized to cause insulin resistance
through increasing inflammation (152) and circulating free fatty acid levels (153). Lifestyle
changes in diet and exercise can play a large role in both preventing and managing T2D (154).
However, if changes to diet and exercise are insufficient in restoring resting euglycemia, insulin
as well as pharmaceutical agents such as metformin, sulfonylureas, and thiazolidinediones can be
used for treatment (155).

1.6.3 Type 1 Diabetes
T1D manifests in patients in a complete insulin deficiency caused by autoimmune
destruction of β-cells (156). The mechanism of autoimmune destruction by T cell response to βcell specific antigens has been characterized, but the underlying cause of the autoimmune
response is still unknown (157). The underlying pathology of T1D is made more complicated
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with the existence of a subset, called Type 1B, that displays an idiopathic destruction of β-cells
(158).
Unlike in T2D patients, T1D patients are fully dependent on exogenous insulin for
survival. Without an exogenous supply, the loss of insulin function results in persistent
hyperglycemia and is fatal (156). Through continued insulin therapy, T1D patients can regulate
their blood glucose to near-normal levels and experience minimal diabetes-related complications
(159). However, insulin therapy carries the risk of acute hypoglycemia in the case of
misadministration of excess insulin, which can result seizures, loss of consciousness, and even
death.

1.6.4 Role of Glucagon in Diabetes
Diabetes is known widely as a disease of insulin. Indeed, due to the therapeutic impact of
insulin in the treatment for both T1D and T2D, research efforts have been heavily
insulinocentric. However, hyperglucagonemia and impaired glucose response has been observed
in diabetic patients (Figure 8) (160-162). Furthermore, several studies have reported that
inhibiting glucagon can restore euglycemia in the absence of insulin (163, 164), demonstrating
the significance of glucagon and glucagon dysregulation in the pathology of diabetes as well as a
potential therapeutic avenue for diabetes treatment. Efforts in targeting glucagon have been
attempted through glucagon receptor antagonists. However, treatment with these agents was
associated with unwanted side effects in exacerbated hyperglucagonemia, hyperlipidemia, and
hypertension (165). As an alternative, targeting glucagon secretion directly could offer a safer
and more efficient route to treating hyperglucagonemia and diabetes. This requires an improved
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understanding of the α-cell and the mechanisms governing glucagon secretion to identify
potential therapeutic targets.

Figure 8. Changes in insulin and glucagon secretion in diabetic patients. In nondiabetic
subjects, insulin and glucagon secretion levels track accordingly and timely in response to
changes in blood glucose levels in response to carbohydrate ingestion, resulting in a quick
restoration of euglycemia and hormone levels. In diabetic patients, disruptions in insulin and
glucagon secretion can be observed, resulting in persistent hyperglycemia that is partially
alleviated with insulin infusion. While a lack of an insulin response can be observed,
hyperglucagonemia persists for an extended duration post carbohydrate ingestion,
contributing to the elevated blood glucose levels. Reproduced with permission from (166).
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Chapter 2
Juxtacrine Signaling Leads to RhoA Mediation of Glucagon Secretion

2.1

Introductory Comments

2.1.1 Juxtacrine Regulation of Islet Hormone Secretion
As the most recently discovered form of regulation of hormone secretion in pancreatic
islets, not much is yet known about the juxtacrine signaling pathways, although there is growing
recognition of the importance of islet architecture and intraislet communication. So far, three
juxtacrine pathways have been identified and characterized in the context of insulin and
glucagon secretion in the islet. These juxtacrine signaling arise from the protein interactions
between cell adhesion molecules (CAMs), the Fas/FasL system, and the EphA/ephrin-A system.
Various CAMs are expressed in pancreatic islets, primarily E- and N-cadherins (87) and
NCAMs (86). Cadherins form cell surface homodimers and play important roles in formation of
adherens junctions as well as cellular signaling through catenin and other signaling pathways. In
islets, loss of E- and N-cadherin function resulted in the inability of β-cells to aggregate and
disrupted proper islet development in mice (87). Beyond the simple role in holding islets
together, CAMs play a direct part in regulating GSIS, as loss of E-cadherin (88, 89) and NCAM
function (90) attenuated GSIS in rodent islets. One possible pathway in which cadherins regulate
GSIS is through interaction with β-catenin (91, 92). At a whole-islet level, evidence suggests that
CAMs play in important role in maintaining proper islet architecture through differential
expression levels in the different islet cell types, with NCAMs preferentially expressed in non βcells (86). Rodent islets dispersed in vitro were able to spontaneously reaggregate into native-like
pseudoislets (167, 168) with restored hormonal activity (29). Disruption of NCAM resulted in
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the inability of proper reaggregation (86, 169), with α-cells distributed throughout the islet. As
NCAM function is independent of Ca2+, this architectural arrangement is likely to be driven at
least in part by Ca2+. This is supported by the observation that reaggregation of β-cells in vitro is
dependent on the presence of Ca2+, whereas non β-cell reaggregation was relatively unaffected
(170). Cadherins have also been implicated to have a role in controlling β-cell proliferation and
apoptosis. In vivo knockout of E-cadherin in β-cells resulted in higher cyclin D2 levels and
increased β-cell mass in mice (88). However, despite increased β-cell mass, E-cadherin KO mice
exhibited reduced GSIS. It is interesting to note that islets from these mice also showed reduced
connexin-36 levels. Dispersed human β-cells displayed lower levels of apoptotic cells when
allowed to bind to E- and N-cadherin coated surfaces (95). In α-cells, genetic knockout of
NCAM in mice resulted in impaired GSIS and GIGS (90). As inhibition of F-actin with
Cytochalasin D restored the secretion of glucagon at low glucose conditions, F-actin is also
likely involved in the NCAM regulatory pathway. Taken together, these results suggest that the
islet utilizes CAMs as a method of contact communication to regulate both the proper formation
and maintenance of islet structure and function. In the context of diabetes, mice with high-fat
diet induced diabetes had significantly lower levels of E- and N-cadherin junctions in β-cells and
displayed increased β-cell mass yet reduced GSIS (96). Further investigation on the effect of
CAMs on the pathophysiology of diabetes will be necessary to explain these observations.
The cell surface receptor Fas and its associated ligand FasL has also been reported to
affect β-cell communication. In addition to playing a central role in β-cell apoptosis (171-173),
the modulation of Fas signaling by FLICE-inhibitory protein (FLIP) has been shown to affect
glucose sensitivity and insulin secretion in mice by controlling the expression of PDX-1, a β-cell
specific transcription factor associated with T2D (174, 175). These studies demonstrate the dual
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function of the Fas pathway as a regulator of β-cell turnover as well as a regulator of insulin
secretion. However, how the β-cells utilize this pathway to communicate at the intercellular level
remains a mystery. Although Fas expression has been observed in α-cells (176), the role of Fas
in α-cells has not been explored.
Tight junctions involving claudins and occludins have also been observed in islets.
Despite being first documented over 40 years ago in human islets (32), and successfully imaged
between β-cells and α-cells (44), our understanding of their function in the islet is extremely
limited. Tight junctions have been found to be associated with gap junctions (74) and increased
in number upon insulin secretion and glucose concentration (177, 178), suggesting a role in
regulating domain accessibility on the plasma membrane. More recent studies have reported an
increase in expression of claudins and occludins in the islet during pregnancy (179, 180) and
maturation (181, 182). In particular, Cldn4 was found to be downregulated in T2D db/db mouse
islets, and genetic knockout resulted in impaired glucose tolerance. Unfortunately, the role of
tight junctions and their associated proteins in insulin or glucagon secretion remains elusive and
requires further investigation.
EphA/ephrin-A signaling has been shown to be important for the proper secretion of
insulin as well as glucagon in response to glucose. As this signaling is central to the work
presented in this thesis, this regulatory pathway will be described in greater detail in the
following sections and chapters.
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2.1.2 The Eph/ephrin System
Named after the human carcinoma cell line it was first discovered in, the Eph
(erythropoietin-producing hepatocellular carcinoma) receptors were first identified and
characterized in 1987 (183). As receptor tyrosine kinases (RTKs), they share the prototypical
RTK topology: a ligand-binding multidomain extracellular domain, a single transmembrane
segment, and a cytoplasmic domain responsible for the intracellular kinase signaling (Figure 9).

Figure 9. Schematic representation of Eph receptor and ephrin ligand structures. EphA
and EphB receptors are structurally highly conserved. They each consist of an ephrin ligand
binding domain, a cysteine-rich region that contains sushi and EGF-like motifs, fibronectin
repeat domains, a single transmembrane domain connecting to the kinase domain, the sterile
alpha motif (SAM) domain, and the post synaptic density/disc large tumor suppressor/zonula
occlidens-1 (PDZ) domain. Although ephrin-A and ephrin-B share a conserved extracellular
Eph binding domain, ephrin-A is bound to the plasma membrane through a GPI anchor, while
ephrin-B has a more orthodox membrane protein structure with a transmembrane domain and
an intracellular PDZ domain.
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Binding of ephrin ligands are required to initiate signal transduction. However, as ephrin ligands
are also membrane bound, Eph activity requires cell-cell contact.
Eph receptors are divided into two classes, EphA and EphB, based on sequence
homology. There are 9 EphA members that bind to 5 ephrin-A ligands, and 5 EphB members
that bind to 3 ephrin-B ligands. The receptor and ligand binding is promiscuous within each
class, with each EphA receptor able to bind to all ephrin-A ligands with varying affinities (Figure
10), with very limited crosstalk with EphB receptors and ephrin-B ligands (184-186). Although
the two classes of receptors are structurally identical, the receptor classes have clear differences
as ephrin-A are bound to the plasma membrane through glycosylphosphatidylinositol (GPI)
anchors and lack cytoplasmic domains while ephrin-B ligands have transmembrane and
cytoplasmic domains.

Figure 10. EphA/ephrin-A binding affinities. Relative binding affinities between EphA
receptors (rows) and ephrin-A ligands (columns) are shown. EphA10 is omitted due to a lack
of binding affinity characterization. EphA/ephrin-A binding shows a high degree of
promiscuity as all EphA receptors shown have binding capabilities to multiple ephrin-A
ligands with varying degrees of affinities. Data taken from (186).
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Figure 11. Mechanism of Eph/ephrin signaling. Eph receptors and ephrin ligands can bind
in trans (upper), leading to receptor clustering and bidirectional signaling. Forward signaling
occurs through the cell expressing the Eph receptor, while reverse signaling occurs through
the cell expressing the ephrin ligand. When the receptor and ligand binds in cis (lower), both
trans binding as well as the bidirectional signaling are inhibited.

The Eph/ephrin system is unique in that its signaling is bidirectional and bimodal (Figure
11). Upon binding of an Eph receptor and an ephrin ligand, signaling occurs simultaneously
through both proteins, giving the receptor a ligand role and the ligand a receptor role. Signal
transduction through the Eph receptor is called forward signaling, while signal transduction
through the ephrin ligand is called reverse signaling (187). Due to the lack of intracellular
domains in ephrin-A ligands, the mechanisms of reverse signaling for these ligands are largely
unknown. In addition to this bidirectional signaling property, Eph/ephrin signaling is bimodal as
binding can occur in trans, between two different cells, and in cis, on the same cell (188).
Conventional signaling occurs when binding occurs in trans. When binding occurs in cis,
signaling transduction does not occur, but instead inhibits trans binding (189).
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Like many other RTKs, ligand-induced receptor clustering occurs following Eph/ephrin
binding and is required for efficient signaling (190). Clustering can be heterogeneous between
different receptors and ligands and the resulting composition, and potentially the oligomeric
state, have functional roles in modulating the downstream signaling (191). Eph receptors have
also been found to cluster independent of ephrin binding if expression levels were abundant
enough to form a nucleating core (192). As these clusters were able to autophosphorylate (193),
they represent a constitutively active functional mode to provide basal levels of signaling in
highly expressing cells.
As the largest known family of RTKs comprising 14 of the 58 known RTKs in humans,
(194), Eph receptors play a role in a wide range of cellular functions from cell adhesion and
migration (195-198), immune cell activation (199-202), and neuronal development and plasticity
(203-206). As suggested by the origin of these receptors, Ephs have been studied for their roles
in cancer. Eph receptors are often overexpressed in many types of cancer cells (207-219) and
have also been shown to play a role in tumor angiogenesis (210). In addition, sequencing studies
revealed many gene mutations on Eph receptors were linked to the development of cancer (211213). Interestingly, it has been recently demonstrated that secreted vesicles expressing Eph
receptors were able to bind to ephrin ligands on nearby cancerous cells to stimulate proliferation,
providing the first example of Eph/ephrin activity that does not require cell-cell contact. The
high level of functional complexity provided by the promiscuity of receptor and ligand binding,
bidirectional and bimodal signaling activity, and clustering allows Eph/ephrin signaling to play
diverse roles in a wide range of cellular functions across many cell types. However, this
complexity also adds to the difficulty in deconvoluting the system to study individual
interactions and functions.
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2.1.3 EphA/ephrin-A Regulation of Insulin Secretion
EphA/ephrin-A signaling has been shown to impact insulin secretion in islets (33). Islets
treated with soluble EphA5 receptors and ephrin-A5 ligands, EphA5-Fc and ephrin-A5-Fc, were
shown to exacerbate and inhibit GSIS, respectively (Figure 12). Treatment with EphA5-Fc,
which stimulates ephrin-A5 reverse signaling and inhibits EphA5 forward signaling in β-cells by
competitively binding to ephrin-A5 ligands, stimulated insulin secretion at low and high (2 and
25 mM, respectively) glucose. Conversely, treatment with ephrin-A5-Fc, which has the opposite
effect, suppressed insulin secretion and greatly attenuated GSIS. Further investigation using
ephrin-A5 knockout (ephrin-A5-/-) mice also resulted in impaired GSIS, which was attributed to
Rac1-mediated F-actin modulation and glucose-dependent decreases in EphA5 phosphorylation

Figure 12. Effect of EphA/ephrin-A signaling on the regulation of insulin secretion.
Mouse pancreatic islets were treated with Fc (control), EphA5-Fc (stimulates reverse
signaling), and ephrin-A5-Fc (stimulates forward signaling) at low and high glucose
concentrations. Insulin secretion is normalized to insulin content and total protein content.
Data are represented as mean values ± SD (n = 3 experiments). Asterisk represents statistical
significance (* p < 0.05). Figure adapted with permission from (33).
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Figure 13. Model of EphA/ephrin-A signaling in glucose-stimulated insulin secretion. In
this model, the forward and reverse signaling swing from an equilibrium to control insulin
secretion. At low glucose conditions, EphA/ephrin-A signaling allows the forward signaling
to suppress insulin secretion. At high glucose conditions, stimulation of PTP activity inhibits
EphA5 forward signaling, resulting in stimulated insulin secretion. Figure adapted with
permission from (33).
caused by PTP cleavage activity. Combining the results, a model was proposed where insulin
secretion depends on balance between the two directions of EphA/ephrin-A signaling, which is
modulated by glucose concentrations (Figure 13). At low glucose levels, EphA forward signaling
dominates due to high receptor phosphorylation and low PTP activity and results in inhibition of
Rac1 and increase in F-actin density, creating a physical barrier to insulin vesicle exocytosis. At
high glucose levels, ephrin-A reverse signaling dominates due to PTP-mediated inhibition of
EphA receptors and results in activation of Rac1 and subsequent depolymerization of F-actin.
Subsequent studies in drug screens supported this model of EphA/ephrin-A mediated
juxtacrine regulation of insulin secretion. Drug screens targeting RTK activity (100) and glucose
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homeostasis (101) both revealed EphA inhibitors that increased GSIS in pancreatic islets and a
human β-cell line, EndoC-βH1 cells, in keeping with the model where inhibition of the forward
signaling leads to higher secretion.

2.1.4 EphA/ephrin-A Regulation of Glucagon Secretion
EphA/ephrin-A signaling has also been shown to impact glucagon secretion in islets (34).
Unlike β-cells which express EphA5 and ephrin-A5, α-cells express EphA4 and EphA7 receptors
(97, 98), that also bind to ephrin-A5 ligands. In α-cells, stimulation of EphA4 forward signaling
by ephrin-A5-Fc was shown to inhibit glucagon secretion and inhibition of the forward signaling
by EphA5-Fc was shown to increase glucagon secretion (Figure 14). Specific inhibition of

Figure 14. Effect of EphA4 inhibition on the regulation of glucagon secretion. Glucagon
secretion are shown in mouse pancreatic islets treated with DPHBA, an EphA4 inhibitor, and
in mouse pancreatic islets with a genetic deletion of EphA4 at low and high glucose
concentrations. Glucagon secretion is normalized to total glucagon content and is represented
as mean values + SEM (n = 8 mice). Hash marks represent statistical significance between
condition and control at the same glucose concentration (# p < 0.05, ## p < 0.01, ### p <
0.001). Asterisks represent statistical significance between high and low glucose
concentrations for the same condition (* p < 0.05, ** p < 0.01). Figure adapted with
permission from (34).
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Figure 15. EphA4 forward signaling restores glucose inhibition of glucagon secretion in
dispersed α-cells. Glucagon secretion are shown in dispersed sorted α-cells treated with
ephrin-A5-Fc, EphA5-Fc, and DPHBA at low and high glucose concentrations. Glucagon
secretion is normalized to total glucagon content and is represented as mean values + SEM (n
= 8 mice). Hash marks represent statistical significance between condition and control at the
same glucose concentration (# p < 0.05, ## p < 0.01). Asterisks represent statistical
significance between high and low glucose concentrations for the same condition (* p < 0.05,
** p < 0.01). Figure adapted with permission from (34).
EphA4 by pharmacological inhibition or genetic knockout (αEphA4-/-) resulted in elevated
glucagon secretion but no effect on insulin secretion. This modulation of glucagon secretion was
also demonstrated to be independent of paracrine effects from insulin and somatostatin.
Critically, stimulation of EphA4 forward signaling restored proper GIGS in dispersed α-cells
(Figure 15), providing a mechanism for the increased glucagon secretion and impaired GIGS
observed when α-cells are removed from the islet environment. Although EphA4 is the dominant
signaling protein, genetic knockout revealed that EphA7 was able to partially compensate for the
loss in EphA4 function. Similar to the model of EphA/ephrin-A regulatory pathway in β-cells,
EphA4 signaling was suggested to modulate F-actin density to regulate secretion (Figure 16).
Stimulation and inhibition of the forward signaling resulted in increased and decreased observed
F-actin density. However, the exact mechanism and the regulatory elements involved in this
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EphA-mediated modulation of F-actin network formation remained unclear, and we
hypothesized that this modulation depends on signaling through Rho-GTPases.

Figure 16. Model of EphA/ephrin-A juxtacrine regulation of glucagon secretion. In this
model, the presence of adjacent β-cells allows ephrin-A to bind to the EphA receptors on the
α-cell, allowing forward signaling to occur. This forward signaling stimulates actin
polymerization, which acts as a barrier to glucagon barrier exocytosis. In conjunction with
paracrine effects from insulin and somatostatin, the combination of the juxtacrine and
paracrine signaling in an islet offers robust regulation of glucose dependent glucagon
secretion. Upon dispersion of the islet, juxtacrine and paracrine signaling are abolished,
resulting in elevated glucagon secretion.
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2.1.5 Rho GTPases
Rho GTPases are a family of GTPases with its first member, RhoA, discovered in 1985
as a Ras homolog (214). Due to their importance in actin assembly in the cytoskeleton (215,
216), interest in Rho GTPases grew rapidly. Currently, there are over 20 known Rho GTPases
divided into 7 subfamilies including Rho, Rac, and Cdc42. Rho GTPases are small (~21 kDa)
monomeric G proteins (217) with lipid moieties that allow them to localize and bind to the
plasma membrane, where they predominantly function (218). As is characteristic of GTPases,
Rho GTPases function by conformationally switching between a GTP-bound active state and a
GDP-bound inactive state. Although this underlying simplicity in design allows these proteins to
function as molecular switches, Rho GTPase activation cycling is strictly regulated by a
multitude of guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs),
and guanine-nucleotide dissociation inhibitors (GDIs) (Figure 17). GEFs activate Rho GTPases
by catalyzing the release of GDP to allow for the binding of the more abundant GTP. GAPs
catalyze the hydrolysis of GTP to GDP ultimately leading to GTPase inactivation. GDIs, inhibit
GTPases by binding preferentially to their GDP-bound state and preventing turnover as well as
sequestering them in the cytoplasm by also binding to the lipid moieties and inhibiting
interactions with the membrane (218, 219). However, this inhibitory function of GDIs gives
them a secondary role as chaperones, shielding the hydrophobic lipid moiety and preventing
misfolding and protecting against proteasome degradation (220). This allows for the Rho
GTPases to accumulate in the cytoplasm as a readily activatable pool to react rapidly to a
signaling stimulus.
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Figure 17. Regulatory mechanism of Rho GTPase activity. Rho GTPases function mainly
at the plasma membrane by anchoring to the plasma membrane with posttranslationally
attached lipid moieties. Switching between their active GTP-bound state and inactive GDPbound state is regulated directly by guanine nucleotide exchange factors (GEFs) and GTPaseactivating proteins (GAPs) and indirectly by guanine-nucleotide dissociation inhibitors
(GDIs). GDIs have a dual function as an inhibitor of GTPase activation and as a chaperone to
stabilize the inactive population in the cytoplasm. Active GTPases proceed with downstream
signaling by interacting with various effectors to affect different cellular processes.

Rho GTPase research over the past few decades has revealed the involvement of these
proteins in a vast range of cellular processes. In addition to virtually all process involving actin,
Rho GTPases have been implicated in other processes such as microtubule regulation, cell
adhesion, cell polarity, cell growth, membrane trafficking, transcriptional regulation, and
neuronal development and maintenance (221, 222). How this diversity in function is possible is
partially evident upon examining the role of Rho GTPases in cell migration studies. Imaging
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studies in migrating fibroblasts using RhoA, Rac1, and Cdc42 FRET biosensors showed that
RhoA was primarily activated at the leading edge immediately upon protrusion, but then
switched off as Rac1 and Cdc42 were activated later, persisting through retraction at the lagging
edge (223-224). Importantly, areas where Cdc42 and Rac1 were activated were mutually
exclusive from where RhoA was active, which is not surprising since RhoA and Rac1 are
antagonistic and mutually inhibitory (225, 226). RhoA also stimulated membrane ruffling and
formation of new focal adhesions. These studies offer insight into how Rho GTPases are utilized
in the cell. By switching on and off the appropriate GTPases in response to signaling stimuli at
specific times and locations via strict regulation by GAPs, GEFs, and GDIs, the cell can exert
very precise control over a myriad of cellular processes.
Eph receptors have been well characterized for their role in modulating actin dynamics
and have been shown to signal though Rho GTPases in various cell types (227-229). EphA5
signaling has been proposed to signal through Rac1 in β-cells to regulate insulin secretion. Due
to the similarities between α- and β-cells as islet endocrine hormone secreting cells, we
hypothesized that EphA signaling in α-cells also signals through Rho GTPases to regulate
glucagon secretion. The data presented in this work supports this hypothesis and identified RhoA
as the primary Rho GTPase involved in the EphA/ephrin-A juxtacrine regulatory pathway of
GIGS.
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2.2

Methods

2.2.1 Experimental Animals, Islet Isolation and Culture
All animal experiments were performed using 10-20 week old male and female mice in
compliance with the Washington University Division of Comparative Medicine. Islet isolation
and culture was performed as previously described (28, 29). Islets were isolated using a 0.075%
collagenase digestion at 34℃ post pancreatectomy and cultured in islet culture media (RPMI
1640 with 10% FBS, 11 mM Glucose, and penicillin-streptomycin) overnight before use. Human
T1D islets were obtained through the Network for Pancreatic Organ Donors with Diabetes
(nPOD). Islets were cultured in islet culture media overnight before use. Table 1 details islet
donor information.
Table 1. Islet donor information
Donor

Age

Gender

Years with T1D

1

19

M

8

2

13

F

7

3

10

M

8

2.2.2 Islet Cell Dispersion and Culture
Islets were washed with HBSS (without Ca2+ or Mg2+, pH 7.4, Gibco) then dissociated in
Accutase (Innovative Cell Technologies) for 5 minutes at 37℃ with intermittent trituration.
Dissociated cells were resuspended in islet culture media for subsequent use. For secretion
assays, cells were plated on tissue culture plates coated with 5 ug/ml rhLaminin-521 (Gibco) in
HBSS (with Ca2+ or Mg2+, pH 7.4, Gibco) at 4℃ overnight and washed with HBSS prior to
plating. Plated cells were allowed to recover overnight prior to use.
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2.2.3 Static Hormone Secretion Assays
Islets and dispersed islets were treated as indicated with 4 µg/ml rodent ephrin-A5-Fc, Fc
(R&D Systems), 100 µg/ml Rhosin hydrochloride, 20 µg/ml ML141, 200 µg/ml NSC23766, 2
µM latrunculin A, 2 µM cytochalasin D (all Tocris Bioscience), and/or vehicle (PBS or DMSO,
0.05%, Sigma-Aldrich) and incubated for 1 hr at 37℃ in islet culture media. The samples were
then equilibrated in KRBH buffer (128.8 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4∙7H2O, 2.5 mM CaCl2, 20 mM HEPES, and 5 mM NaHCO3, pH 7.4, all Sigma-Aldrich)
with 0.1% BSA and 2.8 mM glucose for 30 minutes at 37℃ with continuation of the appropriate
treatments. ~15 islets per experimental condition (both intact islets or dispersed) were incubated
in 100 µL of KRBH buffer at low (1 mM) or high (11 mM) glucose with the appropriate
treatment in 1.5 mL microcentrifuge tubes and incubated for 45 minutes at 37℃. The islets were
transferred to 1.5 mL microcentrifuge tubes containing 100 µL acidified ethanol solution (1.5%
HCl in 70% ethanol) to lyse the cells for homone content. For dispersed islets, the supernatant
was collected and replaced with the acidified ethanol solution. Both secretion and content
fractions were measured for glucagon and insulin content by ELISA (CrystalChem). Secretion
data is presented as percent of total hormone content to normalize for differences in islet size and
cellular population differences.

2.2.4 Data Analysis and Statistics
Data were analyzed with Microsoft Excel and GraphPad Prism. Data are reported as
mean values + SEM. Statistical significance are shown for p-values < 0.05 as determined by
unpaired t-tests.
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2.3

Results

2.3.1 RhoA impairs glucose inhibition of glucagon secretion in pancreatic islets
EphA/ephrin-A have been widely reported to signal through Rho GTPases, as described
in section 2.1.5. In addition, EphA5/ephrin-A5 signaling has been shown to signal through Rac1
to modulate insulin secretion (33). Thus, in order to study the effects of Rho GTPases on
glucagon secretion in α-cell, we focused on three candidates, RhoA, Cdc42, and Rac1, the most
well characterized Rho GTPases. We measured both insulin and glucagon secretion in islets and
dispersed islet cells at low and high glucose upon specific pharmacological inhibition of RhoA,
Cdc42, and Rac1 by Rhosin (230), ML141 (231), and NSC23766 (232), respectively (Figure 18).
In islets, inhibition of RhoA resulted in the loss of glucose dependence of glucagon secretion
while inhibition of Cdc42 and Rac1 did not affect the glucose dependence (Figure 18A). RhoA
inhibition also greatly increased insulin secretion at both low and high glucose concentrations,
while inhibition of Cdc42 and Rac1 had minimal effect on insulin secretion in islets (Figure
18B). However, inhibition of RhoA had minimal effect on both glucagon and insulin secretion in
dispersed islet cells, as with inhibition of Rac1. Instead, inhibition of Cdc42 led to a large
increase in hormone secretion at both low and high glucose concentrations (Figure 18 C, D).
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Figure 18. Effect of Rho GTPase inhibition on hormone secretion. Glucagon (A, C) and
insulin secretion (B, D) were measured in mouse islets (A, B) and dispersed islet cells (C, D)
treated with Rhosin (RhoA inhibitor), ML141 (Cdc42 inhibitor), and NSC23766 (Rac1
inhibitor) at low (black) and high (white) glucose conditions. Data are represented as mean
values + SEM (n ≥ 3 experiments). Hash marks (#) represent statistical significance (p <
0.05) between condition and control at the same glucose concentration. Asterisks (*)
represent statistical significance (p < 0.05) between high and low glucose concentrations for
the same condition.
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2.3.3 Actin Polymerization is Required for Proper Secretion of Glucagon
EphA/ephrin-A signaling has been reported to be correlated to changes in F-actin density
to regulate glucagon secretion in α-cells. In order to further investigate the role of F-actin in
glucagon secretion, we directly inhibited F-actin polymerization with latrunculin A (LatA) and
cytochalasin D (CytoD), two well characterized inhibitors that bind to actin monomers to prevent
polymerization (233-235). Treatment of islets with LatA and CytoD resulted in increased
glucagon secretion at both low and high glucose concentrations (Figure 19).

Figure 19. Inhibition of actin polymerization stimulates glucagon secretion. Glucagon
secretion were measured in mouse islets treated with latrunculin A and cytochalasin D at low
(black) and high (white) glucose conditions. Data are represented as mean values + SEM (n ≥
4 experiments). Hash marks (#) represent statistical significance (p < 0.05) between condition
and control at the same glucose concentration. Asterisks (*) represent statistical significance
(p < 0.05) between high and low glucose concentrations for the same condition.
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2.3.4 Inhibition of RhoA reverses EphA mediated regulation of glucagon secretion
Dispersing α-cells from their islet environment results in elevated glucagon secretion and
is rectified when EphA signaling is reintroduced by addition of ephrin-A ligand. As we
hypothesize that RhoA functions downstream of EphA signaling, inhibition of RhoA will negate
the effects of EphA signaling. We were able to experimentally demonstrate this effect (Figure
20). Treatment of dispersed α-cells with ephrin-A5-Fc resulted in suppression of glucagon
secretion. However, addition of Rhosin resulted in re-elevated glucagon secretion to normal
dispersed α-cell levels.

Figure 20. Rhosin reverses EphA forward signaling mediated suppression of glucagon
secretion. Glucagon secretion were measured in dispersed mouse islets treated with ephrinA5-Fc and ephrin-A5-Fc + Rhosin at low (black) and high (white) glucose conditions. Data
are represented as mean values + SEM (n = 5 experiments). Hash marks (#) represent
statistical significance (p < 0.05) between condition and control at the same glucose
concentration. Asterisks (*) represent statistical significance (p < 0.05) between high and low
glucose concentrations for the same condition.
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2.3.5 EphA Forward Signaling Restores Glucose Inhibition of Glucagon Secretion in Human
T1D Islets
EphA/ephrin-A signaling has been shown to be critical to proper regulation of glucagon
secretion in both mouse and human islets. However, the effect of this regulatory pathway has not
been measured directly in the context of diabetes. In collaboration with Dr. Alessandro Ustione
in the lab, we were able to observe the effect of EphA forward signaling on glucagon secretion in
donor islets from patients with T1D (Figure 21). Glucagon secretion in T1D donor human islets
showed an increase in glucagon secretion with an increase in glucose concentration. Addition of
ephrin-A5-Fc resulted in a reversal in the trend and restored GIGS. However, overall suppression
of glucagon secretion compared to the control was not observed.

Figure 21. Stimulation of EphA forward signaling restores glucose dependent glucagon
secretion in T1D islets. Glucagon secretion were measured in human T1D islets treated with
ephrin-A5-Fc at low (black) and high (white) glucose conditions. Data are represented as
mean values + SEM (n = 4 donors).
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2.4.

Discussion

2.4.1. Role of Rho GTPases in Regulating Insulin and Glucagon Secretion
The data presented in this chapter provide evidence of the importance of Rho GTPases in
the regulation of hormone secretion in the islet. The different Rho GTPase family members
appear to have distinct functions in the islet, as RhoA was able to abolish GIGS in islets, but
Cdc42 and Rac1 did not have such an effect (Figure 18A). However, it seemed Cdc42 assumed a
more significant role in dispersed islet cells, where inhibition of Cdc42 resulted in exacerbated
glucagon secretion (Figure 18C). This apparent difference in the prominence of RhoA and Cdc42
in islets and dispersed islet cells could be a reflection of the distinct, antagonistic roles that RhoA
and Cdc42 were reported to have in many different cellular systems. Interestingly, our results
showed that Rac1 had minimal effect on the secretion of glucagon as well as insulin (Figure 18B,
D), contrary to what was reported previously. One possible explanation for this discrepancy is
that the experiments in this study were done at 1 and 11 mM glucose, as opposed to 2 and 25
mM glucose. This could be indicative of high glucose sensitivity of Rac1. Another possible
explanation is by recognizing the context in which Rho GTPases function. Rho GTPases do not
function as discrete units but as highly coordinated systems with high levels of crosstalk.
Therefore, specific inhibition of Rac1 might be insufficient to affect secretion in the same way as
modulating an upstream signal that could perturb the entire Rho GTPase signaling system to
utilize synergistic and antagonistic effects between Rho GTPases necessary to cause downstream
physiological effects.
As inhibition of RhoA was able to abolish GIGS in islets and change secretory behavior
to a more dispersed-like state, we focused on RhoA as the primary Rho GTPase responsible for
the regulation of glucagon secretion in α-cells. As RhoA inhibition was able to reverse the
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effects of ephrin-A5 in dispersed α-cells (Figure 20), this provides first evidence of RhoA as the
downstream effector of EphA4/7, in keeping with data reported in other cellular systems (226,
227, 236, 237). However, ephrin-A5-Fc treatment, although able to suppress glucagon secretion
at both low and high glucose concentrations, was unable to restore GIGS as observed previously
(34, Figure 15). Although the cause of this discrepancy is unclear, it could be due to differences
in experimental conditions.

2.4.2 Role of Actin in Regulating Glucagon Secretion
F-actin plays a critical role in the proposed model of juxtacrine regulation of glucagon
secretion by the EphA/ephrin-A pathway (34, Figure 16). By directly controlling F-actin
polymerization, we were able to test the significance of F-actin and its role in glucagon secretion.
Although inhibiting F-actin polymerization led to a significant global increase in glucagon
secretion in islets as predicted by the model, the glucose dependence of glucagon secretion was
preserved (Figure 19). This result shows that while F-actin polymerization does play a part in
regulating glucagon secretion, it fails to recapitulate the function of EphA/ephrin-A and is
insufficient by itself in fully regulating glucagon secretion in α-cells. The results highlight the
importance of multiple regulatory pathways that all contribute to the physiological secretory
behavior observed from pancreatic islets. These data also suggest that EphA modulates signaling
pathways other than F-actin polymerization to maintain a robust regulation of glucagon
secretion.
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2.4.3 Role of EphA/ephrin-A Juxtacrine Regulation in T1D
In human donor islets from patients with T1D, we were able to observe dysfunctional
glucagon secretion with impaired GIGS. As T1D results in loss of β-cells, these data are
consistent with loss of juxtacrine signaling that depends on an interface between α- and β-cells,
making the cells behave more “dispersed-like”. Consistent with what was observed previously
(34), treatment with ephrin-A5-Fc was able to restore GIGS. However, overall glucagon
secretion levels were comparable to the untreated islets. Since hyperglucagonemia is a hallmark
in diabetes as well as dispersed α-cells, this could be taken to signify that stimulation of EphA
forward signaling alone in α-cells in T1D islets is insufficient to ameliorate hyperglucagonemia.
While this may be an artifact of a small sample size due to the limited availability of T1D islets,
the inability of ephrin-A5-Fc treatment (EphA forward signaling) to suppress glucagon levels in
T1D islets despite the ability to do so in nondiabetic human islets (34) could be indicative of
dysregulation in other regulatory pathways in diabetic islets that dominate over the ability of the
EphA/ephrin-A pathway to rectify elevated glucagon secretion.

2.4.4 Summary
Our data indicate that Rho GTPases play important roles in islet hormone secretion.
RhoA appears to be the prominent player in regulating glucagon secretion in α-cells, as
inhibition of RhoA results in loss of GIGS. In addition, inhibition of RhoA was able to reverse
the effect of ephrin-A5-Fc treatment on dispersed α-cells, providing first evidence of RhoA
functioning downstream of EphA signaling, consistent with EphA signaling pathways
characterized in other cellular systems. We further focused on the last crucial component of in
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the EphA/ephrin-A juxtacrine model, F-actin. Inhibition of F-actin resulted in elevated glucagon
secretion, as predicted by the model, but was unable to disrupt GIGS, suggesting EphA/ephrin-A
signaling is comprised of more than just F-actin modulation. Finally, we tested the EphA/ephrinA juxtacrine model in the context of T1D. The results using human donor T1D islets, however,
were only partly explained by our model, indicating that our understanding of the cellular
physiology of T1D islets still requires much effort.

48

Chapter 3
Quantitative Fluorescence Imaging of RhoA Activity in α-Cells

3.1

Introduction

3.1.1 Fluorescence Live Cell Imaging
Living cells are extremely complex. Our current levels of biological knowledge and
technology are insufficient to reproduce in vitro the immeasurable number of both intracellular
and intercellular signals and processes occurring in concert. Therefore, in order to study any
cellular processes with any physiological relevance, it is necessary to be able to observe them
directly within live cells.
Although it took over 30 years from the initial discovery of GFP to its first application in
biology (238, 239), fluorescence biosensors have revolutionized the field of cell biology. Since
then, development of fluorescence biosensors and imaging techniques expanded greatly. From
visualizing protein interactions with FRET to diffusion dynamics with FRAP and from specific
spatial control with two-photon excitation to rapid 3D imaging with light sheets, direct
observation of virtually any cellular process in real time is possible, providing a level of
spatiotemporal detail unattainable otherwise.
This chapter will demonstrate the utility of fluorescence biosensors and fluorescence
imaging in characterizing the role of RhoA in the EphA/ephrin-A juxtacrine signaling pathway
in α-cells. The data presented will serve to provide direct evidence supporting RhoA as the
intermediary in the signaling pathway from EphA to F-actin formation.
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3.1.2 Spectral Imaging and FRET
Many biological experiments require visualization of two or more reporter molecules.
One such technique that requires multiple fluorescent biosensors is Förster resonance energy
transfer (FRET), where non-radiative energy transfer occurs from an excited donor fluorophore
to an acceptor fluorophore, resulting in emission of the photon with the properties of the acceptor
emission spectrum. As this energy transfer requires molecular proximity (~5 nm), this technique
is ideal to report on molecular interactions by genetically conjugating donor and acceptor
fluorescent proteins (FPs) to target proteins of interest. Upon binding of the target proteins, the
fluorescent proteins will come into proximity, resulting in FRET. However, quantitative FRET
experiments are made complicated due to spectral overlap in the relatively broad emission
spectra of the FPs. This poses as a significant obstacle in traditional filter-based FRET imaging
experiments as this causes bleed-through of unwanted donor signal into the acceptor detection
channel as well as unwanted acceptor signal in the donor detection channel (240). Attempts to
minimize the bleed-through by stricter bandpass cutoff results in decreased signal to noise ratio.
Due to this, filter-based FRET experiments require laborious correction procedures and
additional measurements (Figure 22A).
One potential solution to this bleed-through is by utilizing spectral imaging. In spectral
imaging, the entire emission spectrum is measured for each pixel in the image through a spectral
detector, resulting in a spatial-spectral datacube (x, y, λ – the 2D image across all the measured
wavelengths). The composite spectral signal can then be linearly unmixed into individual FP
components (241-243) (Figure 22B). As the entire spectrum is collected, the signal to noise ratio
is maximized while negating the need for additional measurements to correct for bleed-through,
which is accounted for by the spectral unmixing. Due to these advantages, spectral imaging is
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ideal for FRET experiments and any imaging experiments requiring multiple fluorescent probes.
However, spectral imaging requires high quality data, as significant noise, especially for low
signals, could contribute to erroneous unmixing. In this chapter, the utility of spectral FRET
imaging will be demonstrated in observing RhoA activity in live α-cells.

Figure 22. Filter-based vs. spectral FRET imaging. Schematic workflow of filter-based
(A) and spectral (B) FRET imaging is described. In filter-based FRET experiments,
unwanted excitation and emission (dashed lines) cause bleed-through into the opposite
channel, resulting in contamination of measured donor and acceptor intensities. This requires
a series of correction measurements and ratiometric calculations to remove the bleed-through
components to get the final corrected donor and acceptor intensities for quantitative FRET
calculations. In spectral FRET imaging, the total spectral signal is measured. As the total
signal is the sum of the donor and acceptor spectral signals, the individual components can be
unmixed via donor-only and acceptor-only reference spectra.
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3.1.3 Visualizing α-Cells
This section serves to introduce the various fluorescent tools utilized in the work
presented in this chapter. These tools demonstrate the utility of fluorescence in identifying cell
types in the islet and directly observing RhoA activity in α-cells in real time. The data presented
in this chapter provide evidence for the role of RhoA as an intermediary in the EphA/ephrin-A
juxtacrine signaling pathway. Hopefully, they will also serve as a foundation and a reference
point for the usage of fluorescent probes in investigating the inner workings of the α-cell.
The islet is made up of many cell types. Therefore, it is crucial to be able to correctly
identify α-cells within the islet milieu for further investigation. Unfortunately, the cell types are
extremely difficult to distinguish by visual examination. In order to resolve this issue, we turn to
a genetic model encoding a FP reporter expressed specifically in α-cells. By utilizing a Cre-lox
system triggered by the glucagon promoter, we can utilize a transgenic mouse line that expresses
a tandem dimer-red fluorescent protein (tdRFP) specifically in α-cells (28, 29) (Figure 23). This
results in a robust expression of tdRFP that allows for easy identification of α-cells in the islet
(Figure 24).
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Figure 23. Schematic of the tdRFP expressing α-cells. The tdRFP expressing gene is
knocked into a mRosa26 promoter with a floxed stop sequence. As the glucagon promoter
activation is specific to α-cells, the CRE recombinase is expressed in α-cells, removing the
stop sequence and allowing expression of tdRFP.

A

B

C

Figure 24. Visualization of tdRFP expressing islets. Islet isolated from a mROSA26tdRFP-Glucagon-iCre transgenic mouse were immunostained with Alexa 488 α-glucagon.
Confocal images of an islet are shown above with detection settings for RFP (A) and Alexa
488 (B). The merged image is shown in C. Scale bar represents 10 µm. Figure obtained with
assistance from Dr. Zeno Lavagnino.
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In order to test the hypothesis that EphA signals through RhoA to mediate F-actin, probes
to report on RhoA activity as well as F-actin formation are necessary. Therefore, we utilized a
FRET biosensor to observe RhoA activity (243) and a GFP-tagged actin chromobody (244) to
visualize F-actin in the α-cell (Figure 25). The RhoA FRET biosensor consists of a mCerulean3YPet FRET pair attached to RhoA and the Rho binding domain of Rhotekin that binds
specifically to active RhoA, resulting in FRET (Figure 25A, B). The actin chromobody consists
of an actin binding nanobody tagged with a TagGFP2 molecule (Figure 25C, D).

Figure 25. Experimental biosensors. (A) Schematic of the RhoA FRET biosensor. Upon
activation of RhoA, the change in conformation allows RBD (Rho binding domain) to bind to
RhoA, bringing the FRET pair in proximity. (B) Visualization of the FRET pair in live cells.
HEK293 cells were transfected with plasmids containing the biosensor and imaged on a
confocal microscope. Scale bar represents 10 µm. (C) Schematic of the actin biosensor. GFP
is attached to nanobodies specific for F-actin. (D) Visualization of the F-actin biosensor in
live cells. HEK293 cells transfected with the actin biosensor were treated with 2 µM
latrunculin A and imaged over time. The loss of F-actin polymerization was able to be
reported in real time.
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3.2

Methods

3.2.1 Experimental Animals, Islet Isolation and Culture
Experimental animal handling and islet isolation were performed as described in Chapter
2.2.1 in compliance with the Division of Comparative Medicine. To generate the fluorescently
labeled α-cells used in the following experiments, transgenic mice expressing Cre-dependent
tdRFP inserted into the ROSA26 locus (mROSA26-tdRFP) was crossed with transgenic mice
expressing iCre (codon-improved Cre) obtained from Dr. Chiyo Shiota.

3.2.2 Islet Cell Dispersion and Culture
Islet dispersion was performed as described in Chapter 2.2.2. After dispersion, cells were
plated on 35 mm glass bottom plates (Cellvis). Plated cells were allowed to recover overnight
prior to adenoviral infection.

3.2.3 Adenovirus Production and Transfection
Adenoviruses for the transfection of the RhoA FRET biosensor (plasmid obtained from
Dr. Klaus Hahn) and the Actin Chromobody (Chromotek) were produced with the AdEasy
system as described in (245). Attractene (Qiagen) was at a ratio of 2.5 µl Attractene per 1 µg
DNA for steps detailing the use of LipofectAMINE in the protocol. Dispersed islet cells were
transfected with adenovirus resuspended in islet culture media the day after dispersion and
incubated ~16 hrs at 37℃. Viral media was replaced with adenovirus-free islet culture media and
incubated for a minimum of 3 hrs at 37℃ prior to experiments.
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3.2.4 Live-cell Imaging
For FRET imaging experiments, dispersed islet cells were equilibrated in KRBH with 2.8
mM glucose in a heated, CO2-controlled stage for 15 minutes at 37℃. Buffer was switched to
KRBH with either 1 mM or 11 mM glucose for experimental use and allowed to equilibrate for
30 minutes before imaging. Applicable treatment was applied after initial imaging and incubated
for 1 hr on stage before re-imaging. The FRET biosensor signals, mCerulean3 and YPet, were
measured using an LSM880 (Zeiss) confocal microscope using a spectral detector and excitation
with a 458 nm laser. For actin imaging experiments, dispersed islet cells were treated with
applicable treatments for 1 hr in islet media before the equilibration steps described above. The
Actin Chromobody signal, TagGFP2, was measured with a 488 nm laser. Buffer compositions
and treatment concentrations are as described in Chapter 2.2.3. Linear unmixing of the FRET
signals was done using the Zeiss Zen imaging software.

3.2.5 Data Analysis
Data were analyzed with Microsoft Excel, ImageJ, and GraphPad Prism. FRET data is
shown as percent change in acceptor:donor ratio pre- and post-treatment. Actin data is shown as
average binned value (1 bin = 5% of radius) normalized to the average value across all bins.
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3.3

Results

3.3.1 EphA Forward Signaling Stimulates RhoA Activity
Previous experiments (Chapter 2.3.4, Figure 20) showed that RhoA inhibition was able to
reverse the effects of EphA forward signaling in dispersed α-cells. To observe directly the role of
RhoA in this signaling pathway, we utilized a FRET biosensor to report on RhoA activity in αcells by inducing expression via adenoviral transfection. Acceptor and donor intensities were
measured by spectral imaging before and after treatment with ephrin-A5-Fc and Rhosin at 1 mM
and 11 mM glucose (Figure 25A). Treatment with ephrin-A5-Fc resulted in an increased
acceptor:donor intensity ratio and treatment with Rhosin resulted in a decreased ratio at both low
and high glucose conditions (Figure 25B). In addition, changes in glucose condition (1 mM to 11
mM and 11 mM to 1 mM) had minimal effect on RhoA activity.
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Figure 26. EphA forward signaling stimulates RhoA activity. Dispersed α-cells
transfected with the RhoA FRET sensor were imaged by confocal microscopy. Spectral
stacks were collected and linearly unmixed to get the donor and acceptor intensities (A). The
changes in the acceptor:donor intensity ratio before and after treatment was measured and
reported as % changes (B). The glucose condition refers to switching the glucose
concentrations from 1 mM to 11 mM (left bar) and 11 mM to 1 mM (right bar). Data reported
as mean values + SEM (n ≥ 33 cells, max 193).
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3.3.2 RhoA Inhibition Disrupts F-Actin Network Formation
The role of RhoA in modulating F-actin has been well characterized in other cell types.
To test if RhoA regulated F-actin in α-cells, we utilized a biosensor to directly visualize F-actin
formation (Figure 26A). Reporter intensities were measured and shown as a function of radial
distance from the center of the cell (Figure 26B). Treatment with Rhosin and CytoD resulted in a
loss of the sharp peak at the edge of the cell, indicating a loss of peripheral F-actin network,
while treatment with ephrin-A5-Fc did not show a change in the F-actin network formation
(Figure 26C).

Figure 27. RhoA inhibition disrupts F-actin formation. F-actin was visualized in
dispersed α-cells using the Actin Chromobody biosensor (A). A schematic of the radial
intensity profile is shown in (B). If a dense F-actin network forms around the cell, this would
be reflected in the profile showing a sharp intensity peak near the periphery of the cell
(upper). Conversely, inhibited F-actin polymerization would result in a broadened peak
(lower). Experimental data is shown in (C) at low glucose (upper) and high glucose (lower).
Variance has been omitted for clarity. Data is shown as mean values (n ≥ 16 cells, max 99
cells) normalized by radial distance and by average value of all intensities.
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3.4

Discussion

3.4.1 EphA Stimulation of RhoA Activity
The work presented in Chapter 2 provided evidence of RhoA as an important regulator of
glucagon secretion in the islet and suggested a link between EphA signaling and RhoA activity.
The work presented in this chapter provides more direct evidence for this association by direct
visualization and quantification of the stimulation of RhoA activity upon stimulation of EphA
forward signaling (Figure 25B) made possible by live cell fluorescence imaging. While RhoA
activity showed minimal change upon change in glucose concentrations in both the glucose
controls and ephrin-A5-Fc treatment, indicating that RhoA is independent from glucose, the
inhibition by Rhosin showed a high degree of glucose dependence. This could be indicative of a
negative feedback mechanism of RhoA inhibition due to another signaling pathway that activates
at high glucose concentrations. However, it is unlikely that this mechanism would be
physiologically relevant as it would require changes to RhoA activity levels only attainable by
external manipulation.

3.4.2 RhoA Modulation of F-actin
Consistent with the predictions of the latter half of our hypothesis, the role of RhoA in
modulating F-actin was able to be directly visualized. Pharmacological inhibition of RhoA
resulted in similar changes to F-actin as direct pharmacological inhibition of F-actin
polymerization. In addition, this effect was seen in both low and high glucose concentrations,
further supporting the glucose independence of the signaling pathway. However, while inhibition
of RhoA activity demonstrated a clear effect on F-actin, stimulatory efforts by ephrin-A5-Fc had
a minimal effect. This could be due to the limitations of the way the data is presented, as small
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changes to the signal could be lost in the normalization process. Another possible reason could
be that EphA forward signaling could result in changes in other aspects of F-actin, such as
stability, remodeling, or its role in trafficking vesicles, as opposed to solely F-actin density.

3.4.3 Summary
The data presented in this chapter provides evidence to establish RhoA as an intermediate
in the EphA/ephrin-A juxtacrine pathway in α-cells. Stimulation of EphA forward signaling
resulted in elevation of RhoA activity in dispersed α-cells. Examination of the effect of RhoA on
F-actin showed that inhibition of RhoA resulted in loss of F-actin density in the cell. This is
consistent with the juxtacrine model, where loss of EphA forward signaling resulted in the
reduction of F-actin density. In addition, the data suggests that these processes are not glucose
dependent, suggesting that the juxtacrine signaling pathway provides a tonic, consistent layer of
regulation in glucagon secretion in the islet.
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Chapter 4
RhoA Modulation of α-Cell Ca2+ Dynamics

4.1

Introduction

4.1.1 Signaling Crosstalk in α-Cells
It is important to keep in mind that the signaling pathways regulating glucagon secretion
in α-cells do not exist as discrete systems, but instead are highly interconnected. Insulin was
shown to activate KATP channels (125) and suppress Ca2+ oscillations in dispersed α-cells (246).
Somatostatin has been shown to suppress secretion by hyperpolarizing the membrane through
activation of GIRK channels in β-cells (126) and activation of G protein-gated K+ channels in αcells (247). Insulin and somatostatin also signal through cAMP modulation in α-cells (129)
which might be important since evidence suggests cAMP influences α-cell electrophysiology.
Studies showed that cAMP activates L-type Ca2+ channels (113, 248) and recruits Ca2+ from
intracellular stores (249-251) to drive an increase in [Ca2+]i resulting in stimulation of glucagon
vesicle exocytosis. On the other hand, glucose modulation of cAMP levels independent of [Ca2+]i
and paracrine influences was observed (252), although the mechanism of this glucose mediated
regulation is still unknown. The downstream signaling of Eph receptors and CAMs through Rho
GTPases has been well characterized in the literature (206, 229, 253, 254), as well as described
in the previous chapters of this thesis. In addition to evidence of convergent signaling pathways,
NCAM was reported to activate EphA3 signaling in GABAergic interneurons (255). Although it
is yet to be tested in α-cells, crosstalk between juxtacrine signals is likely to be important in the
proper regulation of glucagon secretion.
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The current model of EphA/ephrin-A juxtacrine regulatory pathway is seemingly
independent of Ca2+ and paracrine factors, and is focused on signaling through RhoA and F-actin
instead. However, significant evidence exists that supports the link between Rho GTPases and
ion channel activity. RhoA signaling has been shown to inhibit voltage-dependent delayed
rectifying potassium (KDR) channels by both direct binding (256) and by an actin polymerization
dependent uridine triphosphate (UTP) pathway (257). Furthermore, RhoA and Rac1 have been
implicated in regulating the trafficking of K+ channels to the membrane (258, 259). In addition to
K+ channels, RhoA has been shown to inhibit Na+ channels (260, 261) and L-type Ca2+ channels
in cardiac myocytes (262). It is currently unknown if Rho GTPases affect ion channel activity in
α-cells, which would likely influence the glucose sensing electrophysical response of the α-cell.
The work presented in this chapter serves to provide first evidence for the link between the
EphA/ephrin-A juxtacrine regulatory pathway and the electrophysiological regulatory pathway
in the α-cell.

4.1.2 Live Cell Ca2+ Imaging
Since the first discovery of the necessity of Ca2+ in cardiac muscle contractions in frog
hearts almost 140 years ago (263), the calcium ion has established its importance in biology as a
ubiquitous intracellular signaling messenger involved in many crucial biological functions such
as vesicle secretion, neuronal excitability, gene expression, and cell proliferation and apoptosis.
While the absolute concentration of calcium atoms in the cell is high (264), almost all of the
calcium is tightly bound in structures of heavily buffered by calcium-binding proteins. In this
way the intracellular free calcium activity ([Ca2+]i) is actively maintained at a level 20,000 times
lower (~100 nM) than the extracellular concentrations (265). Upon a stimulus signal, rapid influx
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of Ca2+ ions into the cytosol is achieved by entry through Ca2+ ions and release from ER stores
within the cell. Intracellular Ca2+ can then initiate downstream signaling through the numerous
Ca2+ sensors, usually involving conformational changes, such as calmodulin (266), S100 proteins
(267), and G2 domain proteins such as PI3K and protein kinase C (PKC) (268). As the cell is
actively pumping Ca2+ from the cytosol out of the cell or into the ER, this elevation in [Ca2+]i is
transient, resulting in oscillations in [Ca2+]i through cycles of influx and efflux.
The importance of Ca2+ extends beyond controlling intracellular processes to being able
to control higher order coordination in tissues and organs through intercellular Ca2+ signaling.
Through various mechanisms, such as electrical signaling through gap junctions (269), chemical
signaling through neurotransmitters like dopamine and glutamate (270), and mechanical
signaling through flow-sensing cilia (271), organ systems are able to achieve coordination and
synchronization in essential functions such as cardiac muscle contractions (272), memory
formation (273), and renal function (274). Ca2+ dynamics differ between cell types in accordance
to their physiological needs from rapid oscillations in the hundreds of milliseconds to seconds
periodicity domain in cardiac myocytes (275) to slow oscillations in the minutes in β-cells (276).
Because Ca2+ lies at the heart of a myriad of biological processes, understanding Ca2+ dynamics
of a cellular system is often a requisite component in understanding the overall physiology of the
system. Thus, the ability to be able to observe calcium ions in live cells and tissues is of utmost
importance and has been the focus of much development in recent years.
Since the development of the first Ca2+ sensor in the 1970s (277) over a decade after the
first optical measurement of Ca2+ was made using aqueorin (278), many more sensors have been
developed encompassing a wide range of sensitivities and photophysical properties (279, 280).
These sensors can be divided into two classes: chemical sensors and FP-based sensors (Figure
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Figure 28. Mechanisms of Ca2+ sensors. (A) Cells are incubated with esterified forms of
chemical sensors, such as Fluo4, to allow uptake into cells. Once inside the cell, the esters are
cleaved by endogenous esterases, trapping the sensors inside the cell. Upon binding to Ca2+,
fluorescence intensity increases dramatically upon excitation. (B) FP-based sensors, such as
GCaMP6, are most commonly genetically encoded in transgenic animal lines and expressed
within the cell of interest. GCaMP6 consists of a GFP fused to a calmodulin (CaM) and M13,
a myosin light chain kinase peptide sequence. Upon binding to Ca2+, CaM undergoes a
conformational change, allowing binding to M13. The binding of M13 to CaM causes a
conformational change in the GFP to its fluorescently active state.
28). Chemical sensors, including single wavelength sensors such as Fluo-4 and ratiometric
sensors such as Fura-2, are introduced externally and taken up by the cell. Once inside the cell,
they change photophysical properties upon binding to Ca2+. Single wavelength sensors become
fluorescently active upon binding to Ca2+, while ratiometric sensors have a shift in their peak
excitation or emission wavelengths upon binding. Although ratiometric sensors have the
advantage of removing concentration-based artifacts such as uneven dye loading,
photobleaching, and changes in cell volume, it requires the ability to excite or detect at multiple
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wavelengths, making them unsuitable for certain experimental procedures and setups. It is also a
practical limitation that the ratiometric Ca2+-indicator dyes have not kept pace with single
wavelength sensors in terms of dynamic range, sensitivity, and Ca2+ binding kinetics.
As the active forms of these fluorescent Ca2+-sensors are ionized and hydrophilic, they
are therefore unable to cross the plasma membrane into the cell. Thus, the most common way to
resolve this issue has been to first introduce them as uncharged, esterified derivatives that are cell
permeable. Once inside the cell, they are converted to their active form by endogenous esterase
activity and effectively trapped in the cell. Fluorescent protein-based sensors, such as GCaMPs
(Green Fluorescent-Calmodulin Proteins), are genetically encoded chimeric protein constructs
with a calcium binding component that induces a conformational change in the FP upon Ca2+
binding to increase fluorescence. FP-based sensors have several advantages, such as being able
to target specific cell types for expression, being more suited for longer and repeating
experiments as chemical sensors are extruded from the cell over time, and being more suited for
in vivo studies, as delivery of chemical sensors become more difficult. However, chemical
sensors offer the advantage of rapid adoption and usage without the need to develop a transgenic
animal line as well as a wider range of Ca2+ affinities and in some instances superior
photophysical qualities, such as dynamic range, signal-to-noise ratio, and response times.
As influx of calcium ions is a necessary trigger for vesicle exocytosis, Ca2+ is an ideal
surrogate reporter to study any changes to α-cell electrophysiology that affect glucagon
secretion. In order to study the effect of RhoA on α-cell electrophysiology, we utilized the
GCaMP6 FP-based sensor (281) in conjunction with the Glucagon-iCre genetic system described
in Chapter 3 to visualize Ca2+ dynamics specifically in α-cells.
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4.2

Methods

4.2.1 Experimental Animals, Islet Isolation and Culture
Experimental animal handling and islet isolation were performed as described in
Chapters 2.2.1 and 3.2.1 in compliance with the Division of Comparative Medicine. To generate
the fluorescently labeled α-cells expressing GCaMP6, transgenic mice expressing Cre-dependent
GCaMP6 was crossed with transgenic mice expressing Glucagon-iCre.

4.2.2 Live Cell Ca2+ Imaging
Islets were equilibrated in KRBH with 2.8 mM glucose for 15 minutes at 37℃ before
transfer to KRBH with either 1 mM or 11 mM glucose for experimental use and allowed to
equilibrate for 20 minutes in a heated, CO2-controlled stage at 37℃ before imaging. 100 µg/ml
Rhosin, 12.5 µm DPHBA (Santa Cruz Biotechnology) or vehicle (DMSO) was added after initial
imaging and incubated for 1 hr on stage before re-imaging. Fluorescence from GCaMP6 was
measured using an LSM880 (Zeiss) confocal microscope with a 488 nm laser excitation. Buffer
compositions are as described in Chapter 2.2.3.

4.2.3 Data Analysis
Data were analyzed with Microsoft Excel, ImageJ, and GraphPad Prism. Time series
images were converted into kymographs and the number of peaks were counted. Data is shown
as change in average frequency of Ca2+ influx events before and after treatment.
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4.3

Results

4.3.1 Inhibition of RhoA Increases Frequency of Ca2+ Influx Events
In order to test whether the EphA/ephrin-A juxtacrine regulatory pathway engages in
crosstalk with the intrinsic/electrophysiological regulatory pathway through RhoA, we utilized
GCaMP6 expressed selectively in α-cells to study changes in Ca2+ activity upon RhoA
inhibition. Ca2+ influx events were observed as bursts of fluorescence (Figure 29). While the
number of influx events decreased over the duration of the experiment, likely due to prolonged
exposure to relatively minimal imaging buffer, pharmacological inhibition of RhoA by Rhosin
resulted in an increase in Ca2+ activity compared to the control at both 1 mM and 11 mM glucose
(30).
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Figure 29. Visualization of Ca2+ dynamics in α-cells. Representative data is shown as
kymographs tracking GCaMP6 fluorescence. Each line represents the timecourse in one αcell and each block represents all the measured α-cells in one islet. Bright bands represent
influx of Ca2+ into the cell, activating GCaMP6, and subsequent return to resting equilibrium.
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Figure 30. RhoA inhibition increases Ca2+ activity in α-cells. Frequency of Ca2+ spikes
were measured in α-cells before and after treatment with vehicle (DMSO) and Rhosin at 1
mM (black) and 11 mM (white) glucose and the change in the average number of spikes/min
after treatment are shown. Data is represented as mean values ± SEM (n > 37 cells, max 44).
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4.3.2 Inhibition of EphA Forward Signaling Increases Frequency of Ca2+ Influx Events
We also tested the effects of inhibiting EphA forward signaling on Ca2+ activity through
pharmacological inhibition by 4-(2,5-dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid (DPHBA),
which was reported to disrupt suppression of glucagon secretion in islets (34). Treatment with
DPHBA showed an increase in Ca2+ events (Figure 31) by negating the natural decline in Ca2+
activity observed in Chapter 4.3.1 (Figure 30).

Figure 31. Inhibition of EphA forward signaling increases Ca2+ activity in α-cells.
Frequency of Ca2+ spikes were measured in α-cells before and after treatment with DPHBA
at 1 mM (black bar) and 11 mM glucose (white bar) and the change in average number of
spikes/min after treatment are shown. Data is represented as mean values ± SEM (n > 21
cells, max 30).
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4.4

Discussion

4.4.1 EphA Forward signaling and RhoA are Involved in Multiple Signaling Pathways
The work presented in this chapter provides evidence that EphA forward signaling and
RhoA are involved not only in the modulation of F-actin, but in the electrophysiology of the αcell. To our knowledge, this is the first data from looking at this pathway in the α-cell. These
data are in agreement with the results in Chapter 2, as inhibition of RhoA was able to disrupt
GIGS, but inhibition of F-actin formation by LatA and CytoD were unable, suggesting that Factin modulation alone is insufficient to explain the disruption of GIGS upon loss of EphA
forward signaling and RhoA activity. As Rho GTPases signal through many downstream
effectors, it is likely that they control multiple aspects of α-cell function, and that many of these
pathways together are needed to achieve the proper glucose response of glucagon secretion.

4.4.2 Heterogeneity in α-Cells
One of the primary challenges of studying α-cell Ca2+ dynamics is the heterogeneity of
the α-cell population. As seen in Figure 29, α-cells exhibited a highly asynchronous response to
both experimental treatment as well as glucose concentrations. This heterogeneity contributes to
the high level of variance in the data and necessitates a larger sample size to discern any change
in behavior. However, as recent reports in β-cells suggest (282), the heterogeneity is also likely
important to α-cell function in the islet.
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Chapter 5
Significance and Future Directions

5.1

Significance
The purpose of the work presented in this dissertation is to further our understanding of

the α-cell and its role in the pancreatic islet to ultimately provide improved therapeutic options
for diabetic patients. Current treatment strategies focus largely on the loss of insulin function and
rely heavily on insulin-based therapies to alleviate hyperglycemia present in diabetes.
Unfortunately, the contribution of hyperglucagonemia to the pathophysiology of diabetes is often
ignored, leaving the potential of glucagon-based therapies untapped. However, this
insulinocentric bias is less by design and more due to our lack of understanding of the
mechanisms that govern glucagon secretion. Currently, only GLP-1 analogs provide the
therapeutic option to target glucagon secretion. Development of new therapeutic targets and
treatment strategies targeting glucagon secretion requires identification of the molecular actors
that govern the regulation of glucagon secretion and an improved understanding of their
functions.
The work described in the previous chapters serves to provide better understanding of the
EphA/ephrin-A juxtacrine regulatory pathway, the most recent and also the least understood
signaling pathway characterized in α-cells. Prior to the findings shown here, the only
components known of this critical regulatory pathway was EphA4/7 forward signaling and Factin regulation. Chapter 2 links α-cell glucagon secretion to the complex world of Rho
GTPases. Although the Rho GTPase family is composed of many members, the key player in
this pathway was able to be narrowed down to RhoA (Figure 32). RhoA demonstrated a
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significant ability to influence changes in both glucagon and insulin, highlighting its potential as
a pharmaceutical target. Chapter 3 provided verification for the role of RhoA as the intermediate
between EphA signaling and F-actin regulation through direct visualization using live cell
imaging. So far, biosensors have only been utilized in α-cells to report on secondary messengers,
Ca2+ and cAMP. The work presented here can hopefully provide a foundation to utilize
fluorescence live cell imaging as a potent tool to delve deeper into the inner workings of the αcell. Lastly, Chapter 4 suggests that the EphA/ephrin-A regulatory signaling is not as simplistic
as we first hypothesized and provides a first look into its role in signal crosstalk to
electrophysiological control within the α-cell.
This dissertation provides the first steps for further investigation in many directions. These
directions and potential experiments will be discussed in greater detail in the next section.

Figure 32. An updated model of regulatory mechanisms of glucagon secretion in α-cells.
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5.2

Future Directions

5.2.1 The Rho GTPase Family
One of the direct continuations of the work presented in this dissertation is further
investigation into the Rho GTPase family. Although RhoA has been shown to have significant
impact in α-cell glucagon secretion and GIGS, Cdc42 was able to increase secretion in dispersed
α-cells (Chapter 2 Figure 18). Investigation of the involvement of Cdc42 in EphA/ephrin-A
signaling in α-cells can be conducted in a manner similar to the experiments in the previous
chapters. Although RhoA, Cdc42, and Rac1 are the three major Rho GTPases, there over 20
members in the Rho GTPase family and over 160 members in the Ras superfamily that the Rho
family is a part of (283). While the thought of investigating 160 GTPases is far from ideal, the
increasing availability of transcriptome data of islet cells (97, 98, 284-290) provides the
resources to identify potential candidate GTPases for further study.
In the work presented here, RhoA, Cdc42, and Rac1 were considered individually.
Inhibitors such as Rhosin, ML141, and NSC23766 are specific inhibitors. While this property
was vital in discerning individual contributions of each GTPase to cellular function, it ignores
the crosstalk between Rho GTPases. For example, it could be the case that Rac1 inhibition did
not have a significant impact on glucagon secretion (Figure 18) due to a compensatory effect of
Cdc42 activity. Singular modulation of the GTPases will be unable to perceive this relationship.
Further experiments investigating the combinatorial modulation of RhoA, Cdc42, and Rac1 will
be important to elucidate potential synergistic, antagonistic, or compensatory relationships
between these proteins that are otherwise hidden.
In order to more efficiently study these GTPases, the ability to activate as well as inhibit
activity will be advantageous. However, specific activators do not exist currently, and attempts to
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pharmacologically stimulate RhoA and Cdc42 with LPA and bradykinin were unsuccessful. One
potential solution to this problem is by utilizing constitutively active isoforms (291) to study
activation.

5.2.2 Downstream Effectors of RhoA Signaling
Rho GTPases function as molecular switches and signal through various downstream
effectors upon activation. Further characterization of these effectors and their specific roles
would contribute to a better understanding of RhoA mediated regulation of glucagon secretion
and provide additional therapeutic targets. One well characterized downstream effector of RhoA
is Rho-associated kinase (ROCK) (292). Several inhibitors of ROCK are available, such as
fasudil (293) and Y-27632 (294), allowing for pharmacological modulation.

5.2.3 Role of Primary Cilia in Juxtacrine Regulation
Primary cilia have been gaining recognition in recent years in their role in intercellular
communication in the islet. Ciliary dysfunction has been linked to T2D (43, 46) and impaired
insulin secretion in a β-cell-specific cilia knockout model was linked to disruption of the
EphA/ephrin-A juxtacrine signaling system (47). The relationship between primary cilia and
EphA/ephrin-A signaling is yet to be investigated in α-cells. However, all of the necessary tools
to test the effects of ciliary dysfunction on the juxtacrine pathway in α-cells are available. An αcell-specific cilia knockout model has been generated (44), and the work presented in the
previous chapters provide all the necessary tools to directly observe and characterize cilia
mediated juxtacrine effects.
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5.2.4 Role of F-actin in Juxtacrine Regulation
Better characterization of this pathway will not only provide improved understanding of
the juxtacrine pathway for potential therapeutic intervention, but also provide the tools to better
modulate F-actin to study its role in hormone secretion. Current understanding of F-actin in the
α-cell is limited to its role as a physical barrier to exocytosis. However, the actin network is a
highly important and dynamic region involved in all aspects of the lifetime of a vesicle, from
trafficking, docking, to exocytosis (295), with many different proteins involved in this process
chain. Thus, investigating the role of RhoA signaling on the vesicle processing aspect of F-actin
will be important in deepening our knowledge of the juxtacrine regulatory pathway and its effect
on glucagon secretion. Several first experiments in this direction would be to look at the effect of
RhoA modulation on vesicle activity through vesicle tracking experiments, as well as the effect
of modulation of key proteins involved in the regulation of F-actin and vesicle exocytosis, such
as cofilin, formins, Arp2/3, complexins, and SNARE proteins.

5.2.5 Role of RhoA in Crosstalk Between Regulatory Mechanisms
Chapter 4 provides an initial glimpse into the potential role of RhoA in mediating crossmechanism regulation. Beyond simply regulating F-actin, RhoA also affected Ca2+ activity in αcells. As direct inhibition of F-actin was unable to disrupt GIGS, it is likely the EphA/ephrin-A
signaling pathway utilizes a different mechanism to maintain GIGS. Regulation of Ca2+ activity
through RhoA is a potential candidate. However, it is unknown whether this is a causative or
correlative result, and further investigation is of high priority. As Rho GTPases have been shown
in the literature to affect ion channel activity through direct interaction and channel trafficking,
electrophysiology studies will be beneficial in exploring this potential link. Studying the effect of
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RhoA modulation on the electrical activity of α-cells while blocking different ion channels will
allow us to identify which ion channels are being affected by RhoA signaling.
While RhoA signaling has been potentially linked to the electrophysiological regulation
of glucagon secretion, it is also likely that RhoA interacts with another signaling hub, cAMP.
RhoA activation was able to counteract cAMP-induced changes in cell morphology in epitheliallike and neuroblastoma cell lines (296), and cAMP was reported to regulate RhoA in many
studies (297-230). If this interaction held true in α-cells, this would effectively intertwine the
juxtacrine regulatory system to the juxtacrine regulatory system. As fluorescent biosensors for
cAMP have been used to great extent in the literature (301, 302), visualization of cAMP and
RhoA is possible in α-cells. Initial experiments should focus on observing the effects of cAMP
modulation and RhoA modulation on RhoA activity and cAMP activity, respectively, through
live cell imaging in α-cells before investigating the effect of insulin, somatostatin, and EphA
forward signaling on these molecules.

5.2.6 Heterogeneity in Ca2+ activity in α-cells
In Chapter 4, changes in Ca2+ activity were measured by changes in the frequency of Ca2+
influx events. The data also showed significant heterogeneity in activity. However, heterogeneity
in Ca2+ activity extends beyond frequency. Closer look at the GCaMP6 intensity traces reveals a
deeper level of heterogeneity that the waveforms of the influx events themselves are also
heterogeneous (Figure 33). It is currently unknown what causes this heterogeneity or if it has
functional importance. Future investigation into the functional value of this heterogeneity should
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focus on establishing the necessary parameters to characterize the waveforms and test whether
the distribution shifts upon perturbing the regulatory signaling pathways in the α-cell.

Figure 33. Heterogeneity in Ca2+ activity extends beyond changes in frequency.
Representative fluorescence intensity traces from GCaMP6 expressing α-cells in intact
mouse islets (Chapter 4) are shown. The different traces show differences in not only
frequency, but in other aspects such as shape, duration, and amplitude.
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5.2.7 EphA/ephrin-A juxtacrine signaling in the context of diabetes
EphA/ephrin-A signaling provides an extremely attractive target for potential therapeutic
strategies as it has demonstrated importance in regulating both insulin and glucagon secretion. In
addition, due to its role in cancer and neurological pathologies, significant advances have been
made in developing the molecular tools to modulate Eph receptor activity, including antibodies,
small peptides, miRNA inhibitors, and small molecules (303). As the majority of these potential
therapeutic candidates have not been utilized in the context of diabetes, they provide very
convenient tools to start investigating the role of the EphA/ephrin-A regulatory pathway in the
context of diabetes. To date, there have been only two studies investigating the effects of several
small molecule inhibitor of EphA5 on insulin secretion in vivo (100, 101), and none investigating
glucagon secretion. Therefore, it will be greatly worthwhile to apply the tools available in
modulating EphA/ephrin-A activity in a diabetic mouse model. A relatively simple first
experiment would be to test the effect of stimulating EphA4 forward signaling in a T1D mouse
model through intraperitoneal injection of ephrin-A5-Fc (304-306) or treatment with Doxazosin,
an EphA2/4 activator (307, 308).
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5.3

Concluding Remarks
This dissertation provides initial efforts in characterizing a largely unknown regulatory

pathway in the α-cell. Thus, more so than providing any groundbreaking mechanistic revelations,
I believe the true value of the work provided here is in providing inspiration for further
investigation into the profoundly complex physiology of the α-cell. Establishing the role of
RhoA in glucagon secretion added an additional layer of complexity to our current understanding
of regulation of glucagon secretion provided by the profound signaling prowess of Rho GTPases
in regulating many biological functions, and will hopefully serve as a stepping stone for further
research into Rho GTPases not only α-cells, but all islet cell types. In addition, I believe the
research and ideas presented in this dissertation highlights the importance of considering the
regulatory pathways of glucagon secretion not only as parallel signaling pathways, but as an
intertwined amalgamation of crosstalking components where the crosstalk itself is critical in
maintaining the robust physiology of α-cells.
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